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Abstract 
Obesity develops when energy intake exceeds energy expenditure. Defect in the 
function of brown fat and skeletal muscle, two of the major tissues that contribute 
towards energy expenditure, lead to the development of obesity and metabolic 
syndrome. Our previous findings suggest that Tyk2 deficient mice become obese and 
develop the metabolic syndrome. Tyk2, which is a tyrosine kinase of the JAK-STAT 
signaling family, is important for optimal brown development and function. Since brown 
fat and skeletal muscle, both are derived from the Myf5+ lineage of mesenchymal stem 
cells, we also characterized the role of Tyk2 in the development and function of skeletal 
muscle. We found that Tyk2 deficient mice do not display a structural defect in skeletal 
muscle development; however, the function of skeletal muscle is severely impaired in 
these mice. Expression of troponins, which regulate the muscle contraction and muscle 
creatine kinase, which regulates the levels of phosphocreatine, a major fuel for skeletal 
muscle, is downregulated in Tyk2 deficient mice. Skeletal muscle mitochondria also 
display an abnormal morphology along with decreased respiration capacity, which is a 
function of decreased activity of complex IV of the electron transport chain. Interestingly, 
Tyk2 deficient mice also exhibit an increased proportion of fast, glycolytic, Type II fibers 
in the skeletal muscle. Using an in-vitro system for skeletal muscle differentiation, we 
found that Tyk2 levels increase during differentiation, suggesting a role for Tyk2 in 
proper development and function of the skeletal muscle.  
Our previous studies suggested that a kinase-inactive (Tyk2KD) form of Tyk2 is also 
efficient in restoring the function of Tyk2 deficient brown fat preadipocytes. We 
generated transgenic mice that expressed a wild type (Tyk2WT) and kinase inactive 
 
 
(Tyk2 KD) form of tyk2 in brown fat and skeletal muscle under Myf5 cre and in skeletal 
muscle using MCK cre mice. Expression of Tyk2 using the Myf5 cre (E8.0) reverts the 
obese and the metabolic phenotype observed in the Tyk2 deficient mice. Interestingly, 
expressing Tyk2 under MCK cre (E13.0) also reverts the obese phenotype, suggesting 
that the temporal and spatial expression of Tyk2 is critical in regulating energy 
expenditure. 
Our studies also highlight the role of Tyk2, not as a kinase, but as a component of the 
transcriptional assembly regulating the expression of genes involved brown fat and 
skeletal muscle differentiation and function.  
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Chapter I: Introduction 
Obesity is a global phenomenon affecting at least 200 billion adults to date. In the 
United States alone, over a third of the population is obese. Obesity in children and 
adolescents has also increased from 5% in the 1980s to 18% in 2012. Obesity is usually 
defined by the body mass index (BMI; weight in kilograms divided by length in squared 
meters, kg/m2). A BMI >25 kg/m2 represents overweight, >30 kg/m2 obese and >40 
kg/m2 morbidly obese individuals (1). Incidence of Type II diabetes is also linked to 
obesity. As such, the world health organization (WHO) estimates that the number of 
diabetics will reach around 300 billion in 2025 (2).  
Obesity is a result of increased energy intake and/or decreased energy expenditure. 
This excess weight is stored in adipose tissue, which consists of fat cells, or adipocytes, 
which have an incredible capacity for storing surplus energy in the form of lipid (3). 
Obesity is also associated with many abnormalities collectively known as the metabolic 
syndrome, including dyslipidemia, increased risk for cardiovascular disease, and 
abnormal glucose metabolism. All of these alterations can easily factor into the 
development of insulin resistance and type II diabetes (4). 
Changing diet and lifestyle are the common treatments suggested for obesity, however, 
in morbidly obese patients, bariatric surgery has been the only effective treatment to 
date (1). Currently, there are drugs that aim at decreasing energy intake by acting on 
the satiety centers in the brain. Nonetheless, decreasing food intake is known to trigger 
the starvation response in mammals and hence these treatments become ineffective 
after a while (5). Developing alternative therapies that will enhance energy expenditure 
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in obese individuals is the need of the hour. Mammals have two major thermogenic 
tissues- Brown Adipose Tissue (BAT) and Skeletal Muscle (SKM), which are involved in 
regulation of energy expenditure. Increasing the thermogenic capacities of these tissues 
and hence increasing overall energy expenditure may provide an alternative means of 
combating obesity.  
1.1: Brown Adipose Tissue in obesity 
Mammals have two functionally different types of adipose tissues- white adipose tissue 
(WAT) and brown adipose tissue (BAT). WAT mainly functions as an energy store 
whereas the main function of BAT is to dissipate energy in the form of heat (6). 
Differences between BAT and WAT are listed in Table 1.1. In rodents BAT is present 
throughout life. Major depots are located primarily in the interscapular region and the 
axillae, whereas minor amounts exist near the thymus and in the dorsal midline region 
of the thorax and abdomen. The activity of BAT in non- hibernating animals is strictly 
related to the environmental temperature with cold exposure inducing its action. In 
neonates and hibernating animals, BAT serves as an important regulator of the body 
temperature via non- shivering thermogenesis.  
Studies on rodent models suggest that BAT also plays an important role in prevention of 
obesity. Transgenic mice with ablated BAT exhibit metabolic syndrome (7). Uncoupling 
protein 1 (UCP1) is unique to brown fat and is responsible for dissipating the 
mitochondrial proton gradient, thus releasing this potential energy as heat. UCP1 null 
mice exhibit an obese phenotype (8). Additional examples of the relevance of BAT 
against the development of obesity come from genetically obese mouse models like the 
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ob/ob and db/db strains where BAT is dysfunctional (9). BAT activity is also lower in 
overweight and obese individuals compared to the lean individuals. Whereas BMI and 
body fat percentage showed an inverse correlation with BAT activity, resting metabolic 
rate exhibited a positive correlation with BAT activity. Interestingly, it has been observed 
that higher levels of BAT might protect against age-related obesity (6).  
The presence of active brown fat depots in human newborns and its role in non-
shivering thermogenesis has been well studied. However little was known about the 
presence of active brown fat depots in adult humans. It was a well-conceived notion that 
brown adipose tissue is rapidly lost postnatally, within the first (few) years of life, and 
that older adults do not possess more than vestigial amounts of brown adipose tissue 
(10).  
The recent discovery with the use of fluorodeoxyglucose positron emission tomography 
(FDG PET) suggested that adult humans possess active brown fat depots (10) has 
sparked a renewed interest in using brown fat thermogenesis as a treatment for obesity.  
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Table 1.1: Differences between WAT and BAT (adapted from (11)) 
 WAT BAT 
Function 
Energy storage in form of fatty 
acids, triglycerides, secretion of 
adipokines 
Heat production, thermogenesis, 
low fat storage capacity 
Location 
Subcutaneous, abdominal, 
perirenal, gonadal 
Intrascapular, paravertebral, 
axillary and perineal 
Macroscopic 
Features 
Sympathetic and parasympathetic 
innervation, small lobules of 
densely packed cells 
Sympathetic innervation, 
Lobular organization with gland-
like structure 
Microscopic 
Features 
One single large droplet, few, 
small elongated mitochondria 
Multilocular, small lipid droplets, 
abundant, large, round 
mitochondria 
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1.1.1: Development of brown fat 
Brown adipose tissue (BAT), a unique organ to mammals, is developed in the later 
stages of embryonic development (12).  Its major function is dissipation of energy as 
heat, for defense against cold (12, 13). Brown fat, is developed from the Myf5+ lineage 
of mesenchymal stem cells (14), Myf5 is one of the earliest myogenic factors to be 
expressed and determines the myogenic lineage (15).  Brown fat, hence, is a close 
relative of skeletal muscle than white adipose tissue (WAT). Functionally, WAT and BAT 
carry entirely different functions, the major function of WAT being storage of energy 
whereas of BAT being dissipation of energy as heat. Although, WAT and BAT share 
some common adipogenic factors in development, BAT development occurs early in 
embryogenesis, whereas it is not until after birth that WAT depots are developed (13). 
Let’s take a quick look at some of the transcription factors important for BAT 
development.  
a) C/EBP and PPARs 
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription 
factors belonging to the nuclear receptor superfamily. The three known subtypes 
PPARα, PPARγ and PPARδ have different tissue distributions and play a key role as 
regulators of glucose and lipid homeostasis as well as in cell proliferation, differentiation 
and inflammatory responses (16). PPARγ plays a central role in differentiation of both 
brown and white adipocytes (17). The C/EBP (CCAAT/enhancer-binding proteins) 
family consists of 6 members- C/EBPα, C/EBPβ, C/EBPγ, C/EBPδ, C/EBPε and 
C/EBPζ (18). Of the C/EBP family, C/EBPα and C/EBPβ were identified as key 
transcription factors driving fat cell differentiation (18). C/EBPs function cooperatively 
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with PPARγ and promote a transcriptional cascade that promotes and maintains the 
stable differentiated state of adipocytes (19). Interestingly, ectopic expression of 
C/EBPβ in white fat cells has been shown to promote the expression of BAT selective 
genes (17).  
b) PGC1α 
PPARγ coactivator 1α (PGC1α) was identified from brown fat cells as a cold-inducible 
coactivator of PPARγ and other nuclear hormone receptors (20). PGC1α is an important 
regulator of mitochondrial biogenesis (21) and plays an important role in regulating the 
function of mitochondria-rich BAT. Ectopic expression of PGC1α in white adipocytes 
has been shown to induce the expression of UCP1 and promote differentiation toward 
the brown fat phenotype (22). Despite its importance in the thermogenic function of 
BAT, PGC1α still remains dispensable for differentiation of BAT. 
c) PRDM16 
PRD1-BF1-RIZ1-containing homologous domain containing protein 16 (PRDM16) was 
identified in a screen that involved determining the transcriptional factors selectively 
expressed in BAT (23). PRDM16 is highly enriched in BAT as compared to WAT and 
when ectopically expressed in white preadipocytes and fibroblasts, it can initiate 
complete brown fat differentiation. Expression of PRDM16 is not induced during cold 
exposure, suggesting that it is only acting as a brown fat determinant and not in its 
function. Interestingly, mutating the DNA binding residue in PRDM16 does not alter its 
ability to initiate brown fat differentiation nor its interaction with PGC1α, suggesting that 
PRDM16 acts in a transcriptional complex to regulate brown fat determination (23). 
Knockdown of PRDM16 in brown adipocytes induces the expression of skeletal muscle 
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specific genes like MCK, MyoD and Myogenin, suggesting that PRDM16 may also act 
as a Myf5+ lineage specific determinant (24). 
1.1.2: Brown fat in Thermogenesis 
Brown fat is mainly involved in maintaining the body temperature via nonshivering 
thermogenesis. Nonshivering thermogenesis is independent of shivering, which occurs 
in the skeletal muscle. Studies from the 1950s demonstrated that following 
norepinephrine injection, there was an increase in BAT thermogenesis. Recent studies 
have shown that cold induced adaptive thermogenesis is UCP1 dependent and requires 
activation of the sympathetic nervous system, of which norepinephrine is the primary 
signaling component (25). Cold induced responses can also be mimicked by injecting 
mice with norepinephrine. The hypothalamus motor neurons senses any changes in 
temperature and activates the sympathetic nervous system. Thermogenesis in BAT is 
activated by the nor-epinephrine released by the sympathetic nervous system, mainly 
by activation of the β3 adrenergic receptors. This leads to an increase in intracellular 
cAMP concentration, downstream of the G-protein coupled β3 adrenergic receptors and 
thus activation of PKA, which triggers lipolysis. Increased lipolysis lead to an increased 
cellular concentration of free fatty acids which are transported to mitochondria, leading 
to the activation of mitochondrial electron transport chain and the mitochondrial 
uncoupling protein UCP1 (26).  
The mitochondrial electron transport chain (ETC) consists of a series of four complexes 
(Complex I-IV) and electron carriers (coenzyme Q,cytochrome c). The flow of electrons 
via these complexes pumps protons across the inner mitochondrial membrane, thus 
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generating a proton gradient across the inner mitochondrial membrane. The proton 
gradient then drives the synthesis of ATP as protons flow passively back into the 
mitochondrial matrix through a pore that is associated with ATP synthase (or complex 
V) to generate ATP from ADP and Pi. 
The uncoupling proteins (UCPs) belong to a class of mitochondrial transporter proteins, 
spanning across the inner mitochondrial membrane. Similar to other mitochondrial 
proton channels like Adenine nucleotide transporter (ANT), UCP1 increases the 
permeability of the inner mitochondrial membrane, allowing the passage of protons 
against the gradient back into the mitochondrial matrix. This releases the stored 
potential energy and is lost as heat, rather than being converted into chemical energy in 
form of ATP by mitochondrial ATP synthase. UCP1 is primarily expressed in the brown 
fat, whereas UCP2 exhibits a global tissue distribution. UCP3 is restricted to the skeletal 
muscle. Besides UCP1, the role of other UCPs in uncoupling mitochondrial ETC from 
oxidative phosphorylation is not well characterized (27). BAT heavily relies on the 
mitochondrial uncouplers for generation of heat.  
11 
 
 
Figure 1.1: UCP1 along with mitochondrial electron transport chain: Mitochondrial 
oxidative phosphorylation begins with the entry of electrons into the ETC, which is 
impermeable to low-molecular-weight solutes. Electrons flow through the four 
membrane bound complexes (Complex I-IV) with the aid of the electron carriers. The 
transfer of the electrons generates a membrane potential (ΔΨm) across the inner 
mitochondrial membrane. UCP1 dissipates this proton gradient, thus releasing the 
potential energy as heat. (Modified from (28)). 
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Figure 1.2: Norepinephrine mediated activation of non-shivering thermogenesis 
in brown fat. Thermogenesis occurs in brown adipocytes with the stimulation of β-
adrenergic receptors (βARs), initiating a signal transduction cascade that produces 
cyclic AMP (cAMP) and activates protein kinase A (PKA), which then activates multiple 
enzymes responsible for converting the catabolic end products of macronutrients 
(carbohydrates, fats (triacylglycerols (TAG) and free fatty acids (FFA)) and proteins) into 
mitochondrial fuel. The electrons generated by the TCA cycle feed into the electron 
transport chain, generating a proton gradient, which is dissipated by UCP1 and heat is 
generated in this process (5). 
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1.2: Skeletal Muscle in obesity  
Skeletal muscle is an important metabolic tissue in mammals. In humans, SKM 
comprises roughly 30-50% of the body mass and handles almost 80-95% of insulin 
mediated glucose uptake (29). Impaired glucose uptake and decreased oxidative 
capacity of skeletal muscle is one of the major contributors toward the pathophysiology 
of obesity and metabolic syndrome. Skeletal-muscle is also a non-adipose site for lipid 
accumulation (29) and plays an important role in fatty acid oxidation thereby controlling 
circulating lipid levels (30). Obesity and metabolic syndrome are correlated with the 
level of physical activity as well as the accumulation of intramyocellular lipids and fatty 
acid oxidation in SKM (30). Skeletal muscles are also specialized to dissipate energy 
directly as heat (figure 1.4) in response to external stimuli and hence important in 
energy expenditure (5). These studies suggest that a defect in SKM plays a significant 
role in the pathogenesis of obesity and metabolic syndrome. 
1.2.1: Structure of Skeletal Muscle 
Skeletal muscle, along with heart, is an important contractile tissue in mammals. The 
smallest contractile unit of skeletal muscle is termed as a sarcomere. A sarcomere 
consists of an assembly of thick filaments (myosin heavy and light chains) and thin 
filaments (actin) inserted between two z-discs and an M line running through the center 
(Figure 1.3). A complex of Troponins (Troponin T, Troponin I and Troponin C) and 
Tropomyosins sit on the thin filaments (31, 32).  
14 
 
 
 
Figure 1.3: Structure of skeletal muscle: Sarcomeric assembly consists of a thick 
filament (composed of myosins) and a thin filament (composed of actin units) arranged 
between two Z-discs and an M line running through the center. Troponins and 
tropomyosines are arranged on the thin filament (31).  
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Muscle contraction is initiated by an incoming action potential from the nerve endings, 
transmitted via the acetylcholine receptors at the neuromuscular junction, which in turn 
triggers the calcium release from the sarcoplasmic reticulum via the Ryanodyne 
receptors (RyR) (5). The increase in cytosolic calcium concentration triggers calcium 
binding to the Troponins, which changes their confirmation, providing a binding site for 
the myosins. This leads to ATP hydrolysis by the myosins and a change in crossbridge 
linking between actin and myosin, thus initiating muscle contraction (33). Sarcoplasmic 
Reticulum Calcium ATPase (SERCA) pumps back the calcium in the sarcoplasmic 
reticulum to cease the contraction. 
The ability of skeletal muscle to generate force depends on the type of Myosin heavy 
chain (MHC) present within the myofiber. Based on the MHC present, skeletal muscle 
fibers can be classified into four fiber types: TypeI, Type IIa, Type IIb and Type IIx. 
Differences between the fiber types are listed in Table 1.2. Type I fibers are the slow 
twitch fibers, which are oxidative in nature owing to their high mitochondrial content. 
They are important for endurance. Type II fibers are fast twitch fibers, IIa being 
moderately fast and IIb and IIx being extremely fast, rely on anaerobic glycolysis for 
energy, which makes them more prone to fatigue than Type I fibers (22). Interestingly, it 
has been observed that obese individuals and type II diabetics have an increased 
proportion of Type II fibers (29). 
An important determinant of the skeletal muscle fiber types is PGC1α. PGC1α was 
shown to be preferentially expressed in Type I fibers (34)and also shown to induce 
mitochondrial biogenesis in skeletal muscle cells (35). Expression of PGC1α in Type II 
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fibers in transgenic mice lead to their conversion to the mitochondria rich, type I fibers 
(34) is the principal fiber type determinant. 
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Table1.2: Fiber types in skeletal muscle  
 
Type I 
fibers 
Type IIa 
fibers 
Type IIx 
fibers 
Type IIb 
fibers 
Contraction time 
Slow 
Moderateley 
fast 
Fast Fast 
Resistance to 
fatigue 
High Fairly high Moderate Low 
Activity used for 
Aerobic 
Long term 
anaerobic 
Short term 
anaerobic 
Short term 
anaerobic 
Maximum duration 
of use 
Hours <30 mins <5 mins <1 min 
Power produced 
Low Medium High Very high 
Mitochondrial 
density 
Very high High Medium Low 
Oxidative Capacity 
High High Moderate Low 
Major Storage fuel 
Triglycerides 
Creatine 
phosphate, 
glycogen 
ATP, creatine 
phosphate, 
glycogen 
ATP creatine 
phosphate 
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1.2.2: Thermogenesis in Skeletal Muscle 
Skeletal muscle, apart from brown fat, is an important organ for thermogenesis. Three 
types of thermogenesis occur in skeletal muscle- exercise induced thermogenesis, non-
exercise induced thermogenesis and cold induced shivering thermogenesis (5). 
Exercise induced thermogenesis is a well studied mechanism of decreasing body fat. 
Non-exercise induced thermogenesis includes maintenance of general posture and 
other activities of daily life. The most well known mechanism of defending the body 
temperature in response to cold is shivering thermogenesis. Shivering is primarily a 
function of skeletal muscle and is the body’s first response to cold. Shivering is known 
to increase oxygen consumption by up to 5 times the basal metabolic rate (BMR) and 
hence a very effective means of energy expenditure (36). A slight drop in core body 
temperature activates the primary motor nerve center in the hypothalamus and triggers 
the signal for skeletal muscle contraction. As the muscle contraction does not translate 
into work, the energy is released as heat. During cold exposure (4-8oC), shivering 
initially sets in, (it can take place for days during longer periods of cold exposure), until it 
is replaced by non-shivering thermogenesis (NST), which is a primary function of brown 
fat. NST is also beneficial because it prevents from any tissue damage to the skeletal 
muscle because of excessive use. Recent studies have also shown that skeletal muscle 
can contribute to NST (37). Skeletal muscle possesses sarcolipin, which uncouples 
SERCA pump from the Ca2+ releasing Ryanodyne receptors and causes futile Ca2+ 
cycling, which leads to generation of heat. This effect was also observed in UCP1 
deleted, brown fat ablated mice, suggesting that skeletal muscle is also capable of NST. 
A potential mechanism for skeletal muscle NST could be through mitochondrial 
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uncoupling, as occurs in BAT. Although skeletal muscle possesses UCP3, a homologue 
of UCP1, its role in mitochondrial uncoupling is highly debated (38). No specific 
uncoupling proteins like UCP1 have yet been identified in the skeletal muscle. 
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Figure 1.4: Shivering thermogenesis in Muscle. Neurotransmitter-mediated opening 
of cell-surface Na+ channels (1) leads to release of Ca2+into the cytoplasm from 
sources both outside the cell (2) and the sarcoplasmic reticulum (3) via the ryanodine 
receptor (RyR). Ca2+ release results in heat generation by ATP hydrolysis (4) during 
both muscle relaxation and actin–myosin crossbridge cycling during sustained 
contraction. Additional heat energy is released when Ca2+ ions are pumped back into 
the sarcoplasmic reticulum by the sarcoplasmic reticulum Ca2+ ATPases (SERCAs) (5) 
(5). 
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1.3: Brown fat and Skeletal Muscle- Two peas in a pod? 
Given the common adipogenic features of both tissues, white fat and brown fat were 
though to share a common developmental lineage. However, recent studies have 
highlighted the fact that brown adipocytes carry a myogenic signature and are derived 
from Myf5+ progenitors that give rise to the muscle cells (24). Although little was known 
about the developmental origins of brown fat at this time, there were some studies that 
suggested the finding that brown fat shares a developmental origin with skeletal muscle. 
Hasty et al showed that myogenin mutant mice have defects in forming skeletal muscle, 
but showed increased brown fat bundles in cervical and interscapular regions (39). This 
finding was confirmed by Kablar et al almost 10 years after Hasty et al reported their 
findings, that mice deficient in the myogenic transcription factors Myf5/Myod, have 
defects in muscle formation, but they show an increased expression of adipose tissue in 
place of muscle bundles (40). They however did not distinguish whether the excess 
adipose tissue was white or brown. Lineage tracing experiments by Atit et al suggested 
that some populations of brown fat, skeletal muscle and dermis all arise from Engrailed1 
(En1) expressing population of the dermamyotome cells, which depends on the Wnt 
signaling pathway (41).  Microarray experiments from the Swedish group Cannon and 
Nedergaard (42) again confirmed the myogenic signature of the brown fat.  Another set 
of independent studies identified PRDM16 as the ‘master regulator’ that controlled the 
brown fat to skeletal muscle cell fate of the Myf5+ cells (24). Interestingly, when 
PRDM16 was knocked out, the Myf5+ cells assumed a myogenic fate, suggesting that 
PRDM16 plays an inhibitory role on differentiation of Myf5+ cells into skeletal muscle. 
Given the common features of brown fat and skeletal muscle (abundance of 
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mitochondria, regulation of energy expenditure and thermogenesis), these two tissues 
make an attractive target for the treatment of obesity. 
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Figure 1.5: Brown fat and skeletal muscle share a common developmental origin. 
(11). 
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1.4: Mitochondria in obesity and metabolic syndrome 
Mitochondria are important organelles in eukaryotes involved in the production of 
chemical energy in form of ATP from oxidation of nutrients consumed. Mitochondria 
have an inner and outer membrane, intermembrane space and a matrix. The inner 
membrane is highly invaginated, forming numerous cristae. Breakdown of glucose by 
glycolysis and tri-carboxylic acid cycle and oxidation of fatty acids generates substrates 
(NADH and FADH2) that feed in to the electron transport chain (ETC) located in the 
inner mitochondrial membrane (43). As mentioned in section 1.1.2, flow of electrons 
across the ETC generates a proton gradient, which is harnessed by the ATP synthase 
to generate ATP by phosphorylation of ADP.  
Mitochondria play an important role in metabolic regulation and hence affect the whole 
body energy homeostasis. Dysfunction of mitochondria can affect energy expenditure 
and hence lead to the development of obesity (43). Studies on insulin resistant 
individuals have highlighted the role of mitochondrial dysfunction- including decreased 
number of mitochondria, decreased expression of the subunits of the electron transport 
chain and also smaller mitochondria in skeletal muscle (30, 44). The mitochondria not 
only show decreased respiration capacity, but also defective cristae formation and 
overall structure. Interestingly expression of PGC1α, which is known to regulate 
mitochondrial biogenesis, is downregulated in patients with Type II diabetes, suggesting 
a co-relation between mitochondria number and development of insulin resistance (22). 
Mitochondria are important for skeletal muscle function, which handles almost 80% of 
insulin mediated glucose uptake and also for production of adequate amounts of ATP 
required for skeletal muscle contraction. Dysregulation of mitochondrial function in 
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skeletal muscle affects their ability to generate enough ATP, thereby decreasing the 
necessary force production required for muscle contraction. This affects the overall 
muscle function (43), leading to impaired substrate utilization (glucose and fatty acids), 
which can lead to the development of obesity and metabolic syndrome (45). 
Mitochondria also possess uncoupling proteins (UCP1, UCP2, UCP3) (46)in their inner 
mitochondrial membranes. UCP1 is primarily present in brown fat whereas UCP2 shows 
a more global distribution. UCP3 is present mainly in the skeletal muscle. So far, only 
UCP1 is considered to be a true ‘uncoupling’ protein. UCP1 dissipates the ETC proton 
gradient as heat, thereby increasing energy expenditure. Brown adipose tissue is also 
extremely rich in mitochondria and any functional defects in mitochondria translate into 
decreased energy expenditure and thermogenesis, which can ultimately result in 
development of obesity (43). 
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1.5: The JAK-STAT pathway 
Discovered in the early 1990s while studying the actions of Interferon on cells, the JAK-
STAT pathway is still being unraveled after twenty years. The JAKs (Janus kinases/ 
Just Another Kinases) and STATs (Signal Transducers and Activators of Transcription) 
are a part of the signal transduction scheme acting downstream of the Interferon (IFN) 
and cytokine receptors and are important for initial innate immune responses. The JAK-
STAT pathway is also involved in regulating a multitude of cellular processes including 
cell growth, differentiation and immune responses (47). 
The cytokine receptors are comprised of a single transmembrane domain and an 
extracellular domain that promotes ligand binding (48). Binding of a ligand causes 
receptor homo or hetero dimerization or multimerization, depending on the ligand. The 
receptors themselves lack any kinase activity, but receptor associated JAKs are brought 
in close proximity and they auto and trans phosphorylate each other, leading to their 
activation. Activated JAKs phosphorylate specific phosphotyrosine residues on the 
receptor, which provides a binding site for the SH2 domain possessing STATs. The 
STATs are also phosphorylated by JAKs, which releases them from the receptors, 
allows them to dimerize, translocate to the nucleus and activate transcription of 
respective genes (47, 49-51). 
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Figure 1.6: The classical JAK-STAT pathway (Adapted from (50)) 
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1.5.1: JAK family of tyrosine kinases 
Mammals have four JAKs- JAK1, JAK2, JAK3 and Tyk2 and seven STATs (STAT1-4, 
STAT5A, 5B and 6). JAK1, JAK2 and Tyk2 are ubiquitously expressed, whereas JAK3 
expression is restricted to the hematopoietic lineage (48, 50). JAKs are 120-140kd 
proteins and share a common structure. The N-terminus of JAKs contains a Band 4.1 
ezrin, radixin and moesin (FERM) domain (JH6-JH7) and an SH2-like domain (JH3-
JH4). The FERM domain of JAKs is implicated in mediating interaction with the cytokine 
receptors.  At the C-terminus, JAKs possess a kinase like (pseudokinase) domain (JH2) 
and a kinase domain (JH1). The kinase like domain does not possess an ATP binding 
catalytic site, however it is important for complete kinase activity of JAKs (48)The 
phenotypes of JAK knockout mice are listed in Table 1.3. Apart from STATS, JAKs are 
known to have other targets including SOCS proteins, IRS1/2,  Grb2 and c-abl, (48). 
JAKs are found on the plasma membrane, associated with their receptors; however 
recent studies have provided a completely new perspective on JAK localization and 
function. JAK2 has been shown to be present in the nucleus of numerous cell types 
including hematopoietic cells, where it was shown to directly phosphorylate Y41 on 
histone H3 (52). JAK1, along with JAK2 was also found to be constitutively present in 
the nucleus of CHO cells (53). Interestingly, JAKs also affect transcription of genes 
which are not STAT dependent. Tyk2 also shows constitutive localization in the nucleus 
of human fibrosarcoma cells (54). Tyk2, along with the receptor complex, was also 
shown to bind the promoters of IFN inducible genes following interferon treatment of 
cells (55). The FERM domain contains an arginine rich region, which is thought to be 
the putative nuclear localization sequence (NLS) for JAKs (54). 
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Figure 1.7: Schematic structure of JAKs (Adapted from  (50)) 
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Table 1.3: Phenotypes of JAK knockout mice (Adapted from (50)). 
Gene Phenotype of mouse knockout 
Cytokines whose signaling requires 
this Jak 
Jak1 
Viable but early postnatal lethal 
owing to neurological deficits; SCID 
Families of receptor with the shared 
subunits γc or gp130; IFNs 
Jak2 
Embryonic lethal owing to a defect of 
erythropoiesis 
IL-3; family of receptors with the shared 
subunit gp130; IFN-γ hormone-like 
cytokines (EPO, GH, PRL, TPO) 
Jak3 SCID, viable and fertile 
Family of receptor with the shared 
subunit γc 
Tyk2 
Viable and fertile; susceptible to 
parasite infection; resistant to LPS; 
resistant to collagen-induced arthritis 
IL-12; LPS 
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1.5.2: Tyk2 - structure, function and what we already know. 
Tyk2 was the first of the JAKs to be discovered (56), and was found to play an important 
role in IFNα/β signaling (57). Most of the early studies on Tyk2 were carried out in Tyk2 
null human fibrosarcoma cells (58). Tyk2 requires the presence of both kinase like 
domain and kinase domain for full catalytic activity (59). Point mutations in the kinase 
like domain also lead to impaired kinase activity of Tyk2 (60). Tyk2 has two Tyrosines in 
the kinase domain (Y1051/1052 in mice), phosphorylation of both is important for 
complete ligand dependent activation of Tyk2, however mutation of the YYs does not 
impair the kinase activity of Tyk2 (61). Interestingly, mutation of catalytic lysine K930 in 
the ATP binding pocket of Tyk2 renders it kinase inactive, and is not phosphorylated 
basally, however it is still capable of being phosphorylated upon IFN treatment (61). 
While deletion of the N-terminus of Tyk2 has no direct effect on its catalytic activity, it is 
indispensible for stabilizing interaction of Tyk2 with its receptors (62). 
Tyk2 knockout mice were generated by three independent groups- Shimoda et al 
replaced the first coding exon with a neo resistant gene cassette (63), Karshigoff et al 
disrupted exons 3-9 (64) and Sheehan et al deleted the 5”UTR and the first coding ATG 
(65). A naturally occurring mutant mouse of Tyk2 was also reported (66), containing a 
single point mutation in the pseudokinase domain. Tyk2 knockout mice are viable and 
fertile. Interestingly, as opposed to what was observed in the in-vitro model, Tyk2 
knockout mice were found to be dispensable for their role in IFNα/β signaling (63, 64). 
Tyk2 however plays an important role in protection from bacterial, protozoan and viral 
infections by activating IL12 mediated IFNγ production in NK and T cells (67). Tyk2 also 
plays an important role in allergic inflammations by regulating the downregulation of Th2 
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mediated antibody production and recruitment of eosinophils in the airways (68). 
Interestingly, Tyk2 knockout mice are Th2 skewed and also show increased IgE 
production (68). Tyk2 deficient pro-B cells were shown to have a decreased 
mitochondrial respiration capacity (69). Recent studies from our lab have highlighted a 
novel role of Tyk2 in obesity. It was found that Tyk2 deficient mice become obese with 
age (70) and develop the classical hallmarks of metabolic syndrome (Insulin resistance, 
glucose intolerance). These mice do not have an increased energy intake, however they 
clearly have a deficiency in energy expenditure. Brown fat, a key thermogenic tissue, 
was developmentally and functionally defective in Tyk2 knockout mice. These mice also 
cannot survive in the cold past 12 hours, whereas a wild type a mouse can survive in 
cold i.e 4oC for up to weeks/months. This suggests that in the absence of Tyk2, there is 
both, an impaired shivering response mediated by skeletal muscle and non-shivering 
thermogenesis mainly mediated by the brown fat. Interestingly, Tyk2 knockout mice also 
show exercise intolerance (69) when exercised on a treadmill, suggesting that they may 
have defects in their skeletal muscle function.  
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Figure 1.8: Tyk2 and its various activator cytokines (71). Tyk2 is usually found in 
combination with other JAKs (JAk1 and JAK2) at the cytokine (IL and IFN) receptors.  
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Two cases of Tyk2 deficiency in humans have been reported to date (72, 73). 
Minegashi et al reported a 22 year old Japanese patient that displayed a Hyper-IgE like 
syndrome. Similarly, Kilic et al reported an 8 year old Turkish patient that exhibited a 
trend for elevated serum IgE levels, but not as significantly elevated as the Japanese 
patient. Interestingly, both patients were susceptible to bacterial and viral infections. 
Diagnosis of Tyk2 deficiency reported in the Turkish patient is fairly recent and hence 
limited observations are reported till date, including deafness and a mental condition. 
Studies on Japanese patient are consistent with the observations reported in Tyk2 mice, 
including restricted response to IFNα/β, increased proportion of Th2 cells and 
decreased IFNAR1 expression.  
Given the skewed physiology observed in Tyk2 deficient mice and also human subjects, 
more detailed studies on Tyk2 will help consolidate the role it plays and its targets in the 
various physiological functions, which will help develop novel strategies to overcome 
those deficiencies.  
The following studies presented in this thesis highlight the role of Tyk2 in the lineage 
specific determination of brown fat and skeletal muscle and also in their function.  
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Chapter II: Materials and Methods 
2.1: Reagents and antibodies 
All chemicals and reagents were purchased from Sigma-Aldrich or indicated otherwise. 
Antibodies were purchased from Cell Signaling (mouse monoclonal Stat3), Sigma-
Aldrich (mouse monoclonal alpha-tubulin), Abcam (rabbit polyclonal UCP1, rabbit 
polyclonal PRDM16, mouse monoclonal CEBPβ, rabbit polyclonal PGC1α). Rabbit Tyk2 
antisera was a kind gift of Dr. Birgit Strobl (University of Veterinary Medicine, Vienna, 
Austria). Mouse monoclonal antibodies, MHC2b (antibody developed by Stefano 
Schiaffino), myogenin (antibody developed Woodring Wright) and MyHC (antibody 
developed by Helen Blau) were obtained from the Developmental Studies Hybridoma 
Bank, developed under the auspices of the NICHD and maintained by University of 
Iowa, Department of Biology, Iowa City, IA-52242. MHC2a (goat polyclonal antibody) 
was a kind gift from Dr. Zhen Yan (University of Virginia, Charlottesville, VA).  
2.2: Animals 
All the mice were bred and maintained in the MCV/VCU animal facility according to 
Institutional Animal Care and Use Committee (IACUC) regulations. Male mice were 
used for these studies. Tyk2 deficient mice (C57BL/6) were kindly provided by Dr. Ana 
Gamero (Temple University School of Medicine, Philadelphia, USA). Mice carrying a 
transgene encoding the Wild Type (WT) or Kinase Dead (KD) form of Tyk2, including an 
upstream loxP- flanked stop sequence in the ubiquitously expressed Rosa26 locus were 
generated. These mice were crossed 5 generations to Tyk2-/- mice (on C57Bl6/J 
background) to eliminate interference from endogenous Tyk2 in the studies. Control 
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animals were obtained by crossing WT and KD transgenics with a wild type (Tyk2+/+) 
mouse (on C57Bl6/J background) for 5 generations. Mice (transgenic WT and KD on 
Tyk2-/- and Tyk2+/+ background) expressing the WT or KD form of Tyk2 in BAT (brown 
adipose tissue) and SKM (skeletal muscle) were obtained by crossing WT or KD 
transgenic animals with mice expressing the Cre recombinase under control of the Myf5 
promoter, allowing Myf5 lineage-specific expression of Cre  (24). SKM and Heart 
specific expression of WT or KD form of Tyk2 was obtained by crossing the transgenic 
mice with mice expressing Cre recombinase under control of MCK promotor (Muscle 
Creatine Kinase) (74). Animals from the same mixed background strain generation were 
compared. Mice were genotyped to confirm the expression of the transgene and the 
specific cre recombinase. 
2.3: Genotypings 
Mice were genotyped using a modified HotSHOT genomic DNA isolation protocol. 
Briefly, a tail snip was taken and incubated in 75μL of alkaline buffer (25mM NaOH, 
0.2mM EDTA,pH 12.0) for 30minutes at 95°C. Samples were then cooled on ice and 
then 75L of neutralization buffer (40mM Tris-HCl, pH2.0) was added. Samples were 
vortexed and then centrifuged at 16,000xg for 5 minutes at room temperature. Then 
100L of the reaction (approximately 100ng/L) was removed and stored at -20°C until 
used for genotyping. To determine the genotype of the mice, the following PCR 
reactions were set up. For Rosa, 2L DNA, 0.3l of 10M Rosa1, 0.3l of 10M Rosa2, 
0.3l of 10M EGFP1 and 0.3l of 10M EGFP2 Primers,12.5L 2x GoTaq Hot Start 
Green Master Mix (Promega, Madison, WI) and 5.3 L dH2O were added to a PCR 
tube. The following PCR cycles were used 1) 95°C for 4minutes, 2) 95°C for 30 
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seconds, 60°C for 30 seconds, 72°C for 45 seconds repeated 35 cycles 3) 72°C for 7 
minutes.  Myf5 cre PCR was set as follows- 2L DNA, 1.5l of 10M Myf5F, 1.5l of 
10M Myf5R, 1.5l of 10M Myf5 mutant Primers,12.5L 2x GoTaq Hot Start Green 
Master Mix (Promega, Madison, WI) and 6 L dH2O. For Tyk2 genotyping,  PCR was 
set as follows- 2L DNA, 1.0l of 10M Tyk2F, 1.0l of 10M Tyk2R, 1.0l of 10M 
Primers,12.5L 2x GoTaq Hot Start Green Master Mix (Promega, Madison, WI) and 
8.5L dH2O. For Neo genotyping,  PCR was set as follows- 2L DNA, 1.0l of 10M 
Tyk2F, 1.0l of 10M Neo8, 1.0l of Neo9 10M Primers,12.5L 2x GoTaq Hot Start 
Green Master Mix (Promega, Madison, WI) and 8.5L dH2O. The following PCR cycles 
were used for Myf5, Tyk2 and Neo: 1) 95°C for 3minutes, 2) 95°C for 30 seconds, 55°C 
for 30 seconds, 72°C for 30 seconds repeated 35 cycles 3) 73°C for 5 minutes. For 
MCK cre genotyping,  PCR was set as follows- 2L DNA, 1.0l of 10M MCK F, 1.0l of 
10M MCK R, 1.0l of 10M Primers,12.5L 2x GoTaq Hot Start Green Master Mix 
(Promega, Madison, WI) and 8.5L dH2O. The following PCR cycles were used 1) 95°C 
for 3 minutes, 2) 95°C for 30 seconds, 50°C for 30 seconds, 72°C for 45 seconds 
repeated 35 cycles 3) 72°C for 10 minutes.  The PCR products were resolved on a 1% 
agarose/TBE gel with EtBr (ethidium bromide) to visualize the bands. Sequences of 
primers used for genotypings are listed in Table 2.1. 
2.4: Cell Culture 
Brown fat preadipocytes were isolated as previously described (75, 76). Interscapular 
brown adipose tissue was isolated from newborn Tyk2+/+, Tyk2-/-, Tyk2-/-+WT, Tyk2-/-
+KD mice, minced and subjected to collagenase A digestion (1.5 mg/ml in isolation 
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buffer containing 123 mM NaCl, 5 mM KCl, 1.3 mM CaCl2, 5 mM glucose, 100 mM 
HEPES and 4% BSA) for 40 min at 37oC. The digested tissue was filtered through a 
70μM filter. Collected cells were centrifuged at 1500 rpm at room temperature for 5 min 
and then resuspended in 1 ml of primary culture medium (Dulbecco’s modified Eagle 
medium, 4500 mg/L glucose Gibco, Carlsbad, CA) containing 20% FBS, 20 mM HEPES 
and 1% penicillin-streptomycin), transferred into 12 well plates and grown in a 
humidified atmosphere of 5% CO2 and 95% O2 at 37°C. After 3 days of culture, cells 
were immortalized by infection with puromycin resistance retroviral vector pBabe 
encoding SV40 Large T antigen. 24 hrs after infection cells were split into 10 cm dishes 
and maintained in primary culture media for the next 24 hrs and then subjected to 
selection with puromycin at a concentration of 2 μg/ml in DMEM with 20% FBS for one 
week. 
For differentiation, brown preadipocytes were grown to 100% confluence in the 
differentiation medium: DMEM containing 4500 mg/L glucose, 10% FBS, 20 nM insulin 
and 1 nM triiodothyronine. Fully confluent cells were incubated for 48 h in differentiation 
medium supplemented with Induction medium- 0.5 mM isobutylmethylxanthine (IBMX), 
0.5μM dexamethasone and 0.125 mM indomethacin. After 48 hrs of induction, cells 
were maintained in differentiation medium for 5 days.  
2.5: Constructs and viral transductions 
293T cells, used as packaging cells, were grown in complete DMEM medium containing 
10% FBS and 1% penicillin-streptomycin. Cells were transfected in 10 cm dishes using 
Fugene reagent, 5μg plasmid and 5μg of helper vector. (Roche Diagnostics, 
Indianapolis, IN) according to the manufacturer’s instructions.  Media was changed 24 
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hrs after transfection. The virus-containing medium was collected 48 hrs after 
transfection, centrifuged for 10 min at 500 x g and filtered through 0.45 μm filter. Viral 
supernatants were added to the cells for 24 hrs in the presence of Polybrene (8 μg/ml 
polybrene, Chemicon Int., Temecula,CA), then diluted twice with the fresh medium. The 
next day the viral supernatant was removed and replaced by fresh medium. 
2.6: Mitochondrial preparation 
Skeletal muscle mitochondria were prepared as described previously (77) with a few 
modifications. Briefly, muscles were minced finely with a blade, trimmed clean of visible 
fat and connective tissue, and placed in 4 ml of modified Chappell-Perry (CP) buffer 
(buffer CP1: 100 mM KCl, 50 mM 3-(N-morpholino) propanesulfonic acid (MOPS), 1 
mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 5 mM 
MgSO47H2O) supplemented with trypsin (8 mg per 2g of wet tissue). After 20 min 
incubation at 4°C on a rotator, the digestion was stopped by adding an equal volume of 
CP2 (CP1 supplemented with 5% defatted BSA). The tissue was homogenized using a 
motor-driven Teflon-glass Potter homogenizer (3x). The supernatant was transferred to 
a 50ml falcon tube and centrifuged at 1000 ×g for 5 min at 4°C. Mitochondria containing 
supernatant was transferred to fresh eppendorfs and spun at 7800xg for 10 mins at 4°C. 
Mito pellet was washed 3x with CP1 buffer. The final mitochondrial pellet after 3 washes 
was resuspended in CP1 buffer and protein concentration was measured using the 
Lowry method. 
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2.7: Blue Native-PAGE 
Electrophoresis of mitochondrial proteins in native conditions was performed using 
NativePAGE Novex Bis-Tris Gel System (Invitrogen, Carlsbad,CA), according to the 
manufacturer’s instructions with modifications. All chemicals purchased from Invitrogen 
or stated otherwise. Briefly, mitochondria were solubilized in cold 1x NativePAGE 
Sample Buffer containing DDM (n-dodecyl-β-D-maltoside) in the ratio of 1.6 g of 
detergent per 1 g mitochondrial protein or containing digitonin in the ratio of 6 g of 
detergent per 1 g protein. After 15 min of incubation on ice, the samples were 
centrifuged at 16,000 x g for 30 min at 4oC and supernatants transferred to the new 
tubes. The protein concentration of the lysates was determined using Bio-Rad protein 
assay. Prior to the electrophoresis, 30 μg of the extract was combined with Coomassie 
blue G-250 dye (detergent/dye ratio of 8 g per 1 g). Blue Native-PAGE was run using 4 
– 16% gradient Novex NativePAGE Bis-Tris gels and NativePAGE Running Buffer. The 
conditions of a run were as follows: low temperature (4oC) run, 150 V constant for 60 
min, then the voltage was increased to 250 V constant for the remainder of the run 
(about 60 min), upper (inner) chamber contained dark blue cathode buffer (NativePAGE 
running buffer mixed with 0.02% Coomassie blue G-250 dye) which was exchanged 
after the dye front reached 1/3rd of the gel into the light blue cathode buffer (0.002% G-
250). After the run gels were subjected to Coomassie staining. For Coomassie protein 
staining, the native gels were first placed in 100 ml of Fix solution (40 % methanol, 10 % 
acetic acid) and microwaved on high 60 (950 – 1100 watts) for 45 seconds followed by 
30 min of incubation on an orbital shaker at RT. This procedure was repeated once and 
gels were immersed in EZBlue Coomassie Brilliant Blue G-250 colloidal protein stain 
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(Sigma-Aldrich, Saint Louis, MO) and left on orbital shaker for overnight at RT. Next 
day, staining solution was decanted and gels were de-stained using ultrapure water until 
the desired background was obtained, and they were then scanned. 
2.8: In Gel complex assays 
Following BN-PAGE on mitochondria samples solubilized in 10% DDM, the gel was 
stained as follows for determining the activity of individual ETC complexes. 
Complex I: Gel was incubated with 2mM Tris-HCl, pH 7.4, 0.1mg/mlNADH and 
2.5mg/ml nitroblue tetrazolium at RT for 20 mins. 
Complex II: Gel was incubated with 4.5mM EDTA, 10mM KCN, 0.2mM phenazine 
methosulfate, 84mM succinic acid and 50mM nitroblue tetrazolium in 1.5mM phosphate 
buffer, pH 7.4 at RT for 3 hrs. 
Complex IV: Gel was incubated in 5mg diaminobenzidine dissolved in 9ml of 50mM 
sodium phosphate, pH 7.2, 1ml catalase (20mg/ml), 10mg cytochrome c and 750mg 
sucrose at RT for 3 hrs. 
The color development for bands was preserved by fixing the gels in 50% methanol with 
10% acetic acid for 15 mins. The fixed gels were stored in 10% acetic acid. The 
resulting bands were quantified by densitometry with the help of Image-J software.  
2.9: Oxygen Consumption assay 
Polarographic measurement of oxygen consumption by intact mitochondria was 
performed in a glass chamber equipped with Clark-type oxygen electrode (Strathkelvin 
Instruments, Glasgow, Scotland) as previously described (75). The measurements were 
done at 30oC in 500 μl of a respiration buffer (80 mM KCl, 50 mM MOPS, 1 mM EGTA, 
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5 mM KH2PO4 and 1 mg/ml defatted BSA, at pH 7.4). For glutamate/malate-dependent 
respiration (complex I) 300 μg of mitochondrial protein was used. For succinate-
dependent respiration (complex II), 200 μg of mitochondrial protein was used, and for 
TMPD (N,N,N′,N′-tetramethyl-p-phenylenediamine)/ascorbate (complex IV), 100 μg of 
protein was used. Next, the selected substrates for complex I (20 mM glutamate+5 mM 
malate), complex II (20 mM succinate with 7.5 μM rotenone), or complex IV (1 mM 
TMPD/20 mM L- ascorbate with 7.5 μM rotenone) of the respiratory chain were added 
to the chamber. State 3 respiration was initiated by the addition of 0.2 mM ADP (final 
concentration) followed by state 4 respiration. After state 4 was attained, 2 mM ADP 
was added to the chambers to measure maximum rate of state 3 respiration. Finally, 
0.04 mM uncoupler DNP (2,4-dinitrophenol) was used to measure the uncoupled 
respiration rate. In case of TMPD/ascorbate, only maximum rate of state 3 (2 mM ADP) 
was measurable. At the end of that measurement, 2 mM azide was added to determine 
the specificity of complex IV-dependent oxygen consumption. 
ADP-stimulated (state 3) and ADP-limited (state 4) respirations were defined and 
calculated according to the method of Chance and Williams (75).  
2.10: Histology 
Skeletal muscle was fixed in 10% formalin and were paraffin-embedded. Multiple 
sections were prepared and stained with hematoxylin and eosin (H&E) at the Pathology 
Research Service Facility (VCU Medical Center, Richmond, VA). 
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2.11: Electron microscopy 
Skeletal muscle was fixed in 2% paraformaldehyde- 2% glutaraldehyde in 0.1 M 
cacodylate buffer. The tissue samples were processed and analyzed at the Microscopy 
Core Facility at the Department of Anatomy and Neurobiology (VCU Medical Center, 
Richmond, VA). 
2.12: Oil red O staining  
The Oil red O staining was used to test for lipid accumulation in fully differentiated cells. 
Plates with cells were rinsed once with PBS and then fixed with buffered formalin for 1 
hr at room temperature. Fresh Oil red O working solution was prepared by adding 6 ml 
of the stock solution (0.5 g Oil red O in 100 ml of 2-propanol) to 4 ml of dH2O, mixed 
and filtered through Whatman filter paper. Following fixation the cells were incubated for 
1hr at room temperature with Oil red O stain. Then plates were carefully rinsed several 
times with dH2O and air-dried before collecting images under the inverted microscope.  
2.13: RNA extraction and real-time qPCR 
Total RNA was isolated with TRI Reagent (Molecular Research, Cincinnati, OH), 
according to the manufacturer’s instructions. Briefly tissues were harvested and minced 
finely and resuspended in 1ml TRI-reagent. Samples were incubated for 30 mins on a 
rotator-shaker at 4°C.Then 250L cholorform was added to the Tri Reagent and the 
samples were vortexed for 30 seconds and spun down at 13,200 rpm for 10 minutes at 
4°C. The aqueous phase was taken and 500L of isopropanol was added. Samples 
were vortexed and then incubated at -20oC for 30 minutes. RNA was pelleted at 13,200 
rpm for 15 minutes at 4°C. The supernatant was removed and the RNA pellet was 
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washed with 75% ethanol. The samples were then centrifuged at 13,200 rpm for 10 
minutes at 4°C. Supernatant was removed and RNA pellet was dried at 37°C. RNA was 
then re-suspended in the appropriate amount of DEPC H2O depending pellet size and 
then incubated at 55°C for 10 minutes. Isolated RNAs were treated with DNase 
(Promega, Madison, WI) in a 1:10 ratio with DNase and Buffer and incubated at 37°C 
for 30 minutes. The treatment was stopped by using Stop Buffer (Promega, Madison, 
WI) in a 1:10 ratio and incubated at 65°C for 10 minutes. RNA concentration was 
measured using a nanodrop. cDNA was synthesized from 2 μg of RNA with the Tetro 
cDNA Synthesis Kit (Bioline, Taunton, MA). 2g RNA, 1L Random Hexamer Primer 
Mix, 1L 10mM dNTPs mix were preheated at 95°C for 1 minute then cooled to 4°C. 
Then the 5x RT Buffer, 200U Reverse Transcriptase, 10U RNase Inhibitors, and DEPC 
H2O was added to a final volume of 20L. The PCR was set as follows: 42°C for 50 
minutes, 70°C for 15 minutes and then cooled to 4°C.  
Real-time qPCR was performed using SensiMix SYBR and Fluorescein Kit (Bioline, 
Taunton, MA) according to manufacturer’s instruction. . Briefly, the cDNA was diluted to 
1:20 ratio and then 5L of the cDNA was used as the template for the reaction. The 
reaction mixtures for internal controls were prepared as followed: 12.5L of SYBER 
Green mix, 1L 5M forward primer, 1L 5M reverse primer, and 5.5L of dH2O. For 
any other gene the mixture reaction is as followed: 12.5L of SYBER Green, 2.5L 5M 
forward primer, 2.5L 5M reverse primer, and 2.5L dH2O. All the samples were 
assayed in duplicates and analyzed using a CFX96 Real-Time PCR Detection System 
(Bio-Rad, Hercules, CA). Table 2.2 contains a full list of the primer sequences. Primers 
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for Jak1 and Jak2 were purchased from SuperArray (Qiagen SABioscience, Frederick, 
MD). 
2.14: Protein Extraction 
Cells were lysed in ice-cold extraction buffer (20 mM HEPES, 300 mM NaCl, 10 mM 
KCl, 1 mM MgCl2, 20% glycerol, 1% Triton X-100) with added protease (COMPLETE-
Roche) and phosphatase inhibitor cocktails (Roche, Indianapolis, IN) for 30 min at 4°C. 
For isolation of protein from tissues, tissues were harvested and minced finely with a 
blade and incubated with ice-cold extraction buffer for 30 mins on a rotator-shaker. After 
lysis, cell debris was removed from the lysates by centrifugation at 13,000 x g for 10 min 
at 4°C. The protein concentration in the supernatants was determined using a Bio-Rad 
protein assay (Bio-Rad, Hercules, CA).  
2.15: Western blot analysis 
Equal amounts of protein were mixed 1:1 with 2X Laemmli sample buffer containing 1 
mM β-mercaptoethanol. Samples were incubated at 95°C for 5 mins and separated 
using SDS-PAGE electrophoresis (Running buffer: 25 mM Tris, 192 mM glycine, 
0.1%SDS). The proteins were transferred to Immobilon-P polyvinyldifluoridine 
membrane (activated by methanol) and soaked in transfer buffer (70% methanol, Tris-
Hcl) (Millipore, Billerica, MA) using a semi-dry transfer apparatus (Bio-Rad, Hercules, 
CA). Membranes were blocked for 1 h at room temperature with 5% non fat dry milk in 
TBS-T buffer (20nM Tris-HCl, pH 7.5, 500mM NaCl, and 0.05% Tween-20) and then 
incubated overnight at 4oC with the indicated primary antibodies in 5%BSA in TBS-T. 
The blots were washed 3x in TBS-T. Secondary antibody was added (5% non fat dry 
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milk in TBS-T buffer) for 1h at room temp. Samples were washed 3x in TBS-T and then 
developed using ECL-Plus (Pierce Thermo Scientific, Rockford, IL). 
2.16: Immunoprecipitation 
250μg whole cell extracts were diluted with in an IP buffer pH 7.4 (150 mM NaCl, 50mM 
Tris-HCl, 1% Triton, 1 mM EDTA with added protease and phosphatase inhibitor 
cocktails (Roche, Indianapolis, IN) at 0.5μg/μl concentration. Samples were incubated 
overnight at 4°C with Tyk2 antibodies (1:100 dilution) and 20μl agarose beads or control 
IgG and agarose beads. Immunoprecipitates were washed five times with 1xPBS with 
protease and phosphatase inhibitor cocktails. Beads were resuspended in laemlli buffer 
with 1 mM β-mercaptoethanol. Samples were incubated at 95°C for 5 mins and beads 
were pelleted. The supernatant was separated by SDS-PAGE and blotted with indicated 
antibodies.  
2.17: Chromatin Immunoprecipation (ChIP) assay 
Tissues were isolated from mice, minced finely and resuspended in 20ml media 
supplemented with 750μl formaldehyde for crosslinking. The samples were incubated 
on a shaker 37°C for 20 minutes. To stop crosslinking, 125mM glycine was added and 
samples were incubated on a shaker at RT for another 10 mins. The samples were then 
spun down at 4°C, 450xg for 10 minutes. The supernatant was removed and pellet was 
resuspended in 5ml PBS (supplemented with protease inhibitors). The samples were 
then homogenised using a glass homogenizer till the homogenate was clear. This 
homogenate was filtered using a 70μM cel strainer to get a single cell suspension. 
Homogenate was aliquoted into eppendorf tubes and frozen at -80°C. Samples were 
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then thawed and spun at 4°C , 7000rpm for 5 minutes. The pellet was resuspended in 
1ml of lysis buffer (1%SDS, 10mM EDTA pH8.0, 50mM Tris-HCl, pH 8.0) and sonicated 
10x 10 sec on-20 sec off cycle. The samples were then spun 4°C, 7000rpm for 10 
minutes. Supernatant (chromatin) was pre-cleared as follows: 100μl supertanant+1ml IP 
buffer (0.01%SDS, 1.1% Triton X, 1.2mM EDTA, 16.7mM Tris-HCl, pH 8.0, 16.7mM 
NaCl) with inhibitors + 10μl ChIP beads (3x washed protein G sepharose beads 
resuspended in equal volume of ChIP buffer with 10μl 1mg/ml BSA/ 100μl beads and 
5μl 10mg.ml red herring DNA/100μl beads) on rotator at 4°C for 30 minutes. Beads 
were pelleted to give a pre-cleared chromatin. 200μl was saved as input. IP was set as 
follows: 1ml pre-cleared chromatin + 5μl antibodies on rotator at 4°C overnight. The 
next day, 50μl ChIP beads were added and samples were incubated on a rotator at 4°C 
for 2hrs. Beads were spun down at 6000 rpm at 4°C for 1 min and were washed 2x 
(10mins rocking at 4°C followed by a spin at 6000 rpm for 1 min) with each of the 
following buffers: ChIP buffer I (0.1%SDS, 1% Triton X, 2mM EDTA, 20mM Tris-HCl, pH 
8.0, 150mM Nacl), ChIP buffer II (0.1%SDS, 1% Triton X, 2mM EDTA, 20mM Tris-HCl, 
pH 8.0, 500mM Nacl), ChIP buffer III (0.25M LiCl, 1% NP.-40, 1% Sodium 
Deoxycholate, 1mM EDTA, 20mM Tris-HCl, pH 8.0) and ChIP buffer IV (10mM Tris-
HCl, pH 8.0, 1mM EDTA). DNA was then eluted from the beads by adding 200μL ChIP 
elution buffer (1%SDS, 0.1M NaHCO3) and rocking for 15 mins at RT. The beads were 
pelleted at 6000 rpm. The supernatant (and also input sample that was saved 
previously) was reverse cross-linked by adding 8μl 5M NaCl followed by o/n incubation 
at 65°C. 1ml PB was addded and samples were purified on miniprep colums. Final DNA 
48 
 
was eluted with 50μl buffer EB. This DNA was then used to set up qPCR for respective 
promoters. 
For setting up ChIP from cells, 1% formaldehyde was added to the media for 10mins to 
fix cells. The cells were then washed with ice-cold PBS supplemented with 125mM 
Glycine and protease inhibitors. The cells were scraped off in 1ml of PBS, transferred to 
an eppendorf and pelleted at 6000 rpm, 4°C for 4 mins. The pellet was resuspended in 
1ml ChIP lysis buffer and protocol was followed as described above. 
2.18: Site-Directed Mutagenesis 
Site-Directed mutagenesis was carried out according to manufactures instructions 
(Strategene). Briefly, a PCR reaction was set as follows-5 µl of 10× reaction buffer, X µl 
(50 ng) of dsDNA template, 1µl (125 ng) of oligonucleotide forward primer, 1 µl (125 ng) 
of oligonucleotide reverse primer, 1 µl of dNTP mix , 1 µl pfu turbo, ddH2O to a final 
volume of 50 µl.  The PCR was set as follows: 1) 95°C for 30 sec 2) 95°C for 30 
seconds, 55°C for 30 seconds, 68°C for 1min/kb of plasmid length, repeated 35 cycles 
3) 72°C for 10 minutes.  The PCR product was digested with Dpn1 at 37°C for 1 hr. 2 µl 
of the digested product was then transformed into XL-gold ultracompetent cells (On ice 
for 15 minutes, heat shock at  42°C for 50 sec, ice for 2 mins. Add 950 µl SOC medium 
and shake at 37°C for 1hr. 50 µl of transformed bacteria was plated onto an ampicillin 
selection plate and incubate o/n at 37°C). The resulting colonies were screened for the 
mutation. 
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2.19: Statistical analysis 
Results are presented as the mean ± SE. Statistical comparison was performed using 
two-tailed Student’s t-test. While interpreting the data results a p-value less than 0.05 
was considered statistically significant and annotated by *.  
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Table 2.1: List of Primers for Genotyping 
Primer Sequence 
Myf5 F CGT AGA CGC CTG AAG AAG GTC AAC CA 
Myf5 R CAC ATT AGA AAA CCT GCC AAC ACC 
Myf5 mutant ACG AAG TTA GGT CCC TCG AC 
Rosa1 F 
CAA CGC CCA CAC ACC AGG TTA G 
Rosa1 R 
GCA CGT TTC CGA CTT GAG TTG CC 
EGFP1 F 
GCA AGC TGA CCC TGA AGT TCA TC 
EGFP1 R 
TCG TCC ATG CCG AGA GTG ATC C 
MCK F 
ATG TCC AAT TTA CTG ACC G 
MCK R 
CGC CGC ATA ACC AGT GAA AC 
Tyk2 F 
TGG ACA AAA TGG AGT GAG TGT AAG 
Tyk2 R 
CTG GGT CAT GGC TGG AAA AGC CCA 
Neo8 
GAT CGG CCA TTG AAC AAG ATG 
Neo9 
CGC CAA GTC CTT CAG CAA TAT 
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Table 2.2: List of Primers for qPCR  
Primer Sequence 
UCP1 
F: CTG GGC TTA ACG GGT CCT C 
R: CTGGGCTAGGTAGTGCCAGTG 
PRDM16 
F: CAGCACGGTGAAGCCATTC 
R: GCGTGCATCCGCTTGTG 
Cidea 
F: TGC TCT TCT GTA TCG CCC AGT 
R: GCC GTG TTA AGG AAT CTG CTG 
MHCI 
F: GCCAACTATGCTGGAGCTGATGCCC- 
R: GGTGCGTGGAGCGCAAGTTTGTCATAAG 
MHC2a 
F: GGCACAAACTGCTGAAGCAGAGGC 
R: GGTGCTCCTGAGGTTGGTCATCAGC 
MHC2b 
F: GAGCTACTGGATGCCAGTGAGCGC- 
R: CTGGACGATGTCTTCCATCTCTCC 
MHC2x 
F:GGCAGCAGCAGCTGCGGAAGCAGAGTCTGG 
R: GAGTGCTCCTCAGATTGGTCATTAGC 
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titin 
F: GGA TGG AAA GGC TAT TGC AC 
R: CCT CGG TGT CTT CAG CT 
Ryr1 
F: GCCATCCTCAGACCCTAGC 
R: CACTGCAGGACCACTTCATC 
Serca1 
F: ACTGGGGTCAGAACTTCGTG 
R: CCAGGGGGTGATGTGTTTCT 
TnnT1 
F: CTTTGATTCCCCCGAAGATT 
R: CCTTTTTCCGCTGTTCAAAG 
TnnT3 
F: CGCTGAGAAGGAGCGGGAA 
R: GCCAGGTAGCTGCTGTAGT 
TnnI1 
F: AGCCCTCTTCACCTGTCTCA 
R: TTACGGGAGGCAGTGATCTT 
TnnI2 
F: GATCTCAGGATGGGAGATGAG 
R:TCTTTCTCCAGCTCTGTGGC 
TnnC2 
F: CACCTTTGGGTGGTGGAGT 
R: GCCTTGAACTCAGCGATCAT 
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Chapter III: Results 
3.1: Tyk2-/- mice have normal skeletal muscle morphology 
Our previous studies have shown that Tyk2-/- mice have defects in brown adipose 
tissue (BAT) formation (70). Since brown adipose tissue and skeletal muscle are 
derived from the same lineage of Myf5+ve mesenchymal stem cells (24), we wanted to 
investigate if SKM of Tyk2-/- mice have any structural defects. Gastrocnemius, 
plantarius and soleus muscle from 12 week old mice were isolated, fixed, sectioned and 
stained with Hematoxylin and Eosin. As seen in Figure 3.1, Tyk2-/- mice exhibit a 
normal skeletal muscle fiber formation and structure. This suggests that Tyk2 is not 
required for differentiation of skeletal muscle.  
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Figure 3.1: Tyk2-/- mice have a normal skeletal muscle morphology: Hematoxylin 
and Eosin staining of Gastrocnemius muscle of 12 week old Tyk2+/+ and Tyk2-/- mice. 
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3.2: Skeletal muscle of Tyk2-/- mice is not hypertrophied 
NMR studies on Tyk2-/- mice indicated that 3 month old Tyk2-/- mice have increased 
lean mass as compared to Tyk2+/+ mice (Gornicka et al, unpublished). To determine 
whether the increased muscle mass is due to increased muscle hypertrophy or 
increased number of muscle fibers, we measured individual muscle fiber area using 
image-J software. As seen in Figure 3.2A, Tyk2-/- mice do not show an increase in fiber 
size nor do they have increased number of fibers in a muscle cross section. We also 
weighed individual Gastrocnemius, plantaris and soleus muscle from Tyk2+/+ and Tyk2-
/- mice. As seen in Figure 3.2B, the gross weights of individual muscle types are not 
significantly changed. This suggests that the increase in muscle mass is not due to 
hypertrophied muscle, but an overall increase in the body muscle mass.  
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Figure 3.2: Skeletal muscle of Tyk2-/- mice is hot hypertrophied. A) Quantification 
of muscle fiber area of a muscle cross section from figure 3.1, using Image-J software 
(n= 6). B) Weights of individual muscle types isolated from 12-14 week old Tyk2+/+ and 
Tyk2-/- mice (n=6), **p<0.01. Data are expressed as mean ± SEM. 
A 
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3.3: Expression of muscle transcription factors is unaltered in SKM of Tyk2-/- 
mice 
Our previous studies indicate that BAT of Tyk2-/- mice show increased expression of 
skeletal muscle specific genes (70), most likely due to an imbalance in commitment of 
the Myf5+ progenitors towards skeletal muscle, mediated by PRDM 16 (24). Since 
Tyk2-/- mice also have increased muscle mass, we investigated whether there is also 
an imbalance in the expression level of muscle specific genes in the skeletal muscle of 
Tyk2-/- mice. As seen in figure 3.3, expression levels of the muscle transcription factors 
MyoD and myogenin, and the uncoupling protein, UCP3, are not changed in Tyk2-/- 
mice. Interestingly, the levels of muscle creatine kinase (MCK) are downregulated in 
Tyk2-/- mice. MCK is responsible for phosphorylation of creatine, which is one of the 
major fuels utilized by SKM. This would suggest an imbalance in energy utilization 
(78)in Tyk2-/- mice. 
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Figure 3.3: Expression of muscle specific mRNAs in Tyk2-/- mice: q-RT PCR on 
gastrocnemius muscle of 12-14 week old Tyk2-/- and Tyk2+/+ mice. (n=6-8 mice per 
group), **p<0.01. Data are expressed as mean ± SEM. 
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3.4: Tyk2-/- mice may exhibit contractile defects 
Since muscle contraction is an important function of the skeletal muscle, we wanted to 
determine if Tyk2-/- mice exhibit any contractile defects. We measured the expression 
of different troponins, which are a part of the sarcomeric assembly and involved in 
muscle contraction. qRT-PCR analysis on SKM of 12-14 week old mice showed that the 
expression of troponins is downregulated in Tyk2-/- mice (Figure 3.4). This suggests 
that Tyk2-/- may play a role in regulating contractility of the skeletal muscle.  
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Figure 3.4: Tyk2-/- mice may exhibit contractile defects: Expression of troponins T1, 
T3, I1 and I2 in GA muscle of 12-14 week old mice measured by qRT-PCR. (n=6-8 mice 
per group). **p<0.01, ***p<0.0001. Data are expressed as mean ± SEM. 
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3.5: Tyk2-/- mice may exhibit defects in calcium signaling 
Since calcium release triggers muscle contraction, we wanted to determine if Tyk2-/- 
mice show a defect in calcium release which could affect the muscle contraction. We 
measured the expression of Ryanodyne and SERCA receptors which are responsible 
for calcium release and calcium take-up after a stimulus. Figure 3.5 suggests that Tyk2-
/- mice may exhibit a defect in calcium mediated contraction and could affect the muscle 
function and its thermogenic capacity.  
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Figure 3.5: Tyk2-/- mice have decreased expression of mRNAs regulating calcium 
release: Expression of SERCA and Ryanodyne receptors in GA muscle of 12-14 week 
old mice measured by qRT-PCR. (n=6-8 mice per group). *p<0.05, **p<0.01. Data are 
expressed as mean ± SEM. 
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3.6: Tyk2-/- do not show defects in sarcomere assembly 
Our previous studies have shown that Tyk2-/- mice may have a defect in shivering 
thermogenesis which is a function of skeletal muscle contraction (70). We wanted to 
determine if these contractile defects in SKM function were due to a disorganised 
sarcomere assembly. We isolated gastrocnemius, plantarius and soleus muscle from 
Tyk2+/+ and Tyk2-/- mice and subjected them to electron microscopy. The electron 
micrographs (Figure 3.6) reveal an organised structure of the sarcomere assembly in 
Tyk2-/- mice, suggesting that the defects in SKM function in Tyk2-/- mice is not due to a 
defect in structural assembly of the skeletal muscle.  
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Figure 3.6: Tyk2-/- mice exhibit a normal skeletal muscle structure: Electron 
micrographs of GA muscle, in 12 week old mice, showing the sarcomere assembly. N = 
4-6 mice per group. 
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3.7: Tyk2-/- mice do not have defects in neuro-muscular junction assembly  
The neuro-muscular junction (NMJ) is responsible for transmitting signals from the 
incoming nerve to the skeletal muscle in response to various stimuli including cold 
exposure, which is responsible for inducing muscle contraction. Since Tyk2-/- mice 
exhibit defects in stimuli induced muscle contraction, we wanted to determine whether 
the defect was due to improper transmission of the incoming signal or due to the 
downstream effectors involved in muscle contraction. To determine this, we isolated 
individual muscle types (gastrocnemius, soleus, plantaris, tibelis anterior, diaphragm) 
and stained them with labelled α-bungarotoxin from snake venom, which binds 
specifically to the Acetylcholine receptors at the NMJ. As seen in figure 3.7, both 
Tyk2+/+ and Tyk2-/- exhibit a normal NMJ assembly (characterized by pretzel shaped 
staining), suggesting that the defects in Tyk2-/- mice lie downstream of the NMJ.  
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Figure 3.7: Tyk2-/- mice have a normal NMJ assembly: a-bungarotoxin staining of 
acetyl choline receptors at the NMJ assembly in GA muscle of 12 week old Tyk2+/+ and 
Tyk2-/- mice. N= 3 mice per group. 
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3.8: Contractile defects in Tyk2-/- are SKM specific 
Apart from skeletal muscle, heart is another contractile tissue with similar contractile 
apparatus. As seen in Figure 3.8, expression of titin, one of the sarcomeric assembly 
proteins is downregulated in SKM, but is unchanged in the heart. This suggests that the 
defect lies specific to the contractile apparatus of skeletal muscle. 
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Figure 3.8: Contractile defects in Tyk2-/- mice are skeletal muscle specific: 
Expression of Titin in GA muscle and heart of 12-14 week old mice measured by qRT-
PCR. (n=6-8 mice per group). **p<0.01. Data are expressed as mean ± SEM. 
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3.9: Tyk2-/- mice have increased glycolytic fibers 
Fast-twitch fibers (glycolytic) contain low numbers of mitochondria and are responsible 
for short term muscle activities. Slow-twitch fibers (oxidative) are rich in mitochondria 
and are responsible for endurance functions. Our previous studies demonstrate that 
Tyk2-/- mice are exercise intolerent (69) and show a relatively lower endurance 
capacity. Since oxidative fibers and mitochondria play an important role in endurance 
function, we wanted to determine whether Tyk2-/- mice show an increased proportion of 
glycolytic fibers which could contribute to this phenotype. As seen in Figure 3.9, Tyk2-/- 
mice show an increased expression of MHC2b (the glycolytic fiber specific myosin 
heavy chain) and a decresed expression of MHC2a (the oxidative fiber specific myosin 
heavy chain) in gastrocnemius (mixed muscle). However, the expression of total myosin 
heavy chains or myogenin (marker of terminal muscle differentiation) are unchanged. 
This suggests that the decreased endurance phenotype is contributed by the increased 
proportion of fast-twitch fibers. 
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Figure 3.9: Tyk2-/- mice have an increased proportion of glycolytic fibers: Protein 
expression of MHCs for Type I (MHC2a), Type II (MHC2b) and total MHCs in whole cell 
extract on GA muscle of 12-14 week old mice was analysed by western blot. 
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3.10: PGC1α is downregulated in SKM of Tyk2-/- mice 
PGC1α plays an important role in skeletal muscle function as it is the key factor that 
determines the different fiber types (fast-twitch versus slow-twitch) and also is involved 
in mitochondrial biogenesis. Since Tyk2-/- mice showed a decrease in the slow, 
oxidative fibers, we wanted to determine if PGC1α was one of the contributing factors. 
RNA was isolated from gastrocnemius muscle of 12 week old mice and PGC1α 
expression was determined by qRT-PCR.  As seen in Figure 3.10, Tyk2-/- mice exhibit 
decreased PGC1α expression, and this downregulation is skeletal muscle specific, 
suggesting that PGC1α is one of the contributing factors towards the Tyk2-/- phenotype. 
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Figure 3.10:PGC1α is downregulated in Tyk2-/- mice: Expression of PGC1α in GA 
muscle and heart of 12-14 week old mice measured by qRT-PCR. (n=6-8 mice per 
group). *p<0.05. Data are expressed as mean ± SEM. 
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3.11: Tyk2-/- mice exhibit altered mitochondria morphology in SKM 
From the previous figure, we know that PGC1α expression is downregulated in SKM of 
Tyk2-/- mice. Since PGC1α is also the master regulator of mitochondrial biogenesis, we 
wanted to determine whether the mitochondria morphology and number was affected in 
SKM of Tyk2-/- mice. Electron micrographs on gastrocnemius (glycolytic) (Figures 
3.11C, 3.11D) and soleus (oxidative) (Figures 3.11A, 3.11B) muscles of 12 week old 
mice reveal that the number of mitochondria is not changed, however the morphology is 
grossly altered (Figures 3.11A, 3.11C). Mitochondria in Tyk2-/- mice appear smaller as 
compared to Tyk2+/+ mice in both Type I (mitochondria-rich) and Type II (mitochondria-
poor) fibers and also show deformed cristae formation. This suggests that Tyk2 may 
play a role in regulating the mitochondrial structure. 
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Figure 3.11:Mitochondria in Tyk2-/- mice are deformed: Representative Electron 
micrographs of Soleus (A),(B) and plantaris (C),(D) muscle in 12 week old Tyk2+/+ and 
Tyk2-/- mice.  
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3.12: Tyk2-/- mice exhibit defects in mitochondrial respiration 
Next, we wanted to determine whether the mitochondria exhibit a defect in function 
along with the structural defects. We isolated mitochondria from skeletal muscle of 12-
14 week old Tyk2+/+ and Tyk2-/- mice and measured respiration on isolated 
mitochondria using a Clark-type oxygen electrode. We measured electron flow through 
Complex I, Complex II and Complex IV by adddition of specific substrates. As seen in 
Figure 3.12, Tyk2-/- mice exhibit decreased Glutamate-Malate (complex I), succinate 
(complex II) and TMPD-ascorbate (Complex IV) dependent respiration. This could be 
due to a defect in activities of all ETC complexes or Complex IV which is the last one in 
the chain.  Figure 3.12, also shows that State 3 (ADP-dependent) and State 4 (ADP-
independent) respiration are both lower in Tyk2-/- mice.  DNP and azide uncoupled 
respiration is also decreased, suggesting that the defects lie in electron flow through 
ETC and not in ATP synthase (Complex V). 
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Figure 3.12: Tyk2-/- mice exhibit a defect in mitochondrial respiration: Oxygen 
consumption was measured from isolated mitochondria of 12-14 week old Tyk2+/+ and 
Tyk2-/- mice using specific substrates (Glutamate-malate for Complex I, succinate for 
complex II and TMPD-Ascorbate for complex IV) in a Clark-type oxygen electrode. State 
3 (ADP dependent), State 4 (ADP-independent), and uncoupled (DNP for complex I and 
II and azide for complex IV) values are represented in the figure. (n= 10-12 mice per 
group) *p<0.05. 
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3.13: Tyk2-/- mice exhibit defect in CIV activity 
To identify which ETC complex contributed to decreased in oxygen consumption in 
skeletal muscle mitochondria, we measured activities of the different ETC complexes 
using an In-gel assay. Isolated mitochondria from skeletal muscle of 12-14 week old 
mice were resolved on a Blue-Native gel to separate the individual complexes and 
enzymatic activities were measured based on colorimetric analysis (79). Figure 3.13 
suggests that the defect lies in activity of Complex IV, which could contribute to the 
overall decreased mitochondrial respiration. 
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Figure 3.13: Complex IV activity is decreased in Tyk2-/- mice: (A) Activities of 
complex I, complex II and complex IV were measured on isolated mitochondria from 12-
14 week old Tyk2+/+ and Tyk2-/- mice using an In-gel assay afterBN-PAGE. (B) 
Quantification of Complex IV activity from (A) using Image-J software.  N=4-6 mice per 
group, *p<0.05. 
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3.14: Decreased ComplexIV activity in Tyk2-/- mice is not due to a defect in 
assembly of the ETC 
Decreased complex IV activity in the SKM mitochondria of Tyk2-/- mice could be due to 
decreased expression of complex IV proteins or a defect in overall assembly of the ETC 
complexes. Figure 3.14A shows that Tyk2-/- mice do not show any changes in the 
expression or assembly of the different ETC complexes, nor the expression of 
mitochondrial proteins (Figure 3.14B) is different between Tyk2+/+ and Tyk2-/- mice, 
suggesting that the defect is activity of complex IV is not due to a structural defect in the 
assembly of ETC components.  
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Figure 3.14: Decreased ComplexIV activity in Tyk2-/- mice is not due to a defect in 
assembly of the ETC: Mitochondria were isolated from 12-14 week old Tyk2+/+ and 
Tyk2-/- mice and resolved on BN-PAGE. Mitochondria solobilised with DDM show ETC 
complexes while mitochondria solubilised using digitonin show ETC supercomplex 
formation. B) Western blot on isolated mitochondria from 12-14 week old Tyk2+/+ and 
Tyk2-/- mice.  
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3.15: Tyk2-/- mice exhibit SKM defects from birth 
We wanted to determine whether the defects seen in SKM of Tyk2-/- mice are present 
from birth or they develop with age.  We isolated RNA from skeletal muscles from 1-3 
day old newborn pups and measured the expression of troponins and MHCs by qRT-
PCR. As seen in Figure 3.15 A, expression of troponins is downregulated in Tyk2-/- 
mice suggesting that the pups also exhibit contractile defects. Figure 3.16B shows that 
expression of MHCI, the slow-oxidative type muscle fiber MHC is downregulated, 
suggesting that Tyk2-/- mice exhibit a developmental defect in SKM function.  
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Figure 3.15: Tyk2-/- mice exhibit SKM defects from birth: Expression of Troponins 
(A) and Myosin Heavy Chains (B) in skeletal muscle 1-3 day old newborn pups 
measured by qRT-PCR. (n=8-10 mice per group). *p<0.05. **p<0.01. Data are 
expressed as mean ± SEM. 
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3.16: Tyk2 is induced during differentiation of C2C12 myocytes 
To determine if Tyk2 is involved during the differentiation of SKM, we used an in-vitro 
approach. We measured the levels of Tyk2 RNA and protein during the differenetiation 
of C2C12 myocytes. As seen in Figure 3.16A, Tyk2 is barely detectable in 
undifferentiated, proliferating myocytes. However, Tyk2 levels increase (~20 fold) soon 
after C2C12 myocytes are induced for differentiation and the upregulation is maintained 
in differentiated myocytes. We also measured the expression of Jak1 and Jak2 (Figure 
3.16B), which are known to be involved in myogenic differentiation. Jak1 is known to be 
upregulated during the proliferation stage (80)and Jak2 is known to be involved in the 
differentiation of C2C12 myocytes (81). This suggests that Tyk2 may be involved in 
differentiation of myocytes and is indispensable for SKM function. 
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Figure 3.16: Tyk2 is induced during differentiation of C2C12 myocytes: Western 
blot analysis (A) and qPCR (B) on whole cell extracts of C2C12 myocytes during the 
course of differentiation.  
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3.17: Restoring expression of Tyk2 in BAT and SKM (Myf5 cre) 
We next wanted to determine whether restroring the expression of Tyk2 in the Myf5 
positive progenitors- BAT and SKM, will reverse the obese phenotype in Tyk2-/- mice. 
Our preliminary results showed that restoring the expression of Tyk2 (Tyk2 WT) in 
Tyk2-/- brown preadipocytes can differentiate into brown fat in-vitro (70). We also 
expressed kinase inactive Tyk2 (Tyk2 KD) in Tyk2-/- preadipocytes as a control for 
kinase activity. To our surprise, expression of Tyk2 KD also induced differentiation of 
brown fat preadipocytes in vitro. To further investigate the role of kinase inactive Tyk2, 
we generated mice carrying Tyk2 (Tyk2 WT) and kinase inactive Tyk2 (Tyk2 KD) 
transgene. These mice were bred with Tyk2-/- mice on C57/Bl6 background. These 
mice were then crossed to Myf5 cre mice (on Tyk2-/- background) to generate 
transgenic mice that expressed either Tyk2 WT (Tyk2WTMyf5) or Tyk2 KD (Tyk2KDMyf5) 
proteins. Tyk2-/- littermate control animals carried the inactive transgene.  Tyk2+/+ 
control animals were generated in a similar fashion, the only difference being that they 
expressed endogenous Tyk2 and carried an inactive transgene. As seen in figure 3.17, 
the transgene was expressed only in BAT and SKM, but not other tissues. 
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Figure 3.17: Expressing Tyk2 in the Myf5 lineage: Whole cell extracts from BAT, 
SKM, WAT and Heart from Tyk2+/+, Tyk2-/-, Tyk2-/-+Tyk2WT, Tyk2-/-+Tyk2KD mice 
were analysed by western blot forTyk2 levels in 4 week old male mice. N= 3-4 mice per 
group. 
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3.18: Tyk2 expression in BAT and SKM restores the obese phenotype 
The first question that we wanted to address using the transgenic model was whether 
mice expressing Tyk2WTMyf5 and Tyk2KDMyf5 revert their obese phenotype. Mice were 
weighed every week for 6 months. The weights are plotted in Figure 3.18. Figure 3.18A 
shows that the lean phenotype is restored in both Tyk2WTMyf5 and Tyk2KDMyf5 mice as 
early as 12 weeks of age and is maintained till the mice are 6 months old (Figure 
3.18B). This suggests that kinase activity of Tyk2 is not required for its role in regulating 
the obese phenotype and that restoring expression of Tyk2 in BAT and SKM is sufficient 
to revert the obese phenotype of Tyk2-/- mice.  
  
89 
 
A 
 
B 
 
 
Figure 3.18: Tyk2 expression in BAT and SKM restores the obese phenotype: 
Body weight of mice at 12 weeks (A) and 24 weeks (B) fed a breeder chow diet. (n= 15-
24 mice per group). ***p<0.0001. Data are expressed as mean ± SEM. 
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3.19: Tyk2 expression in BAT (Myf5 cre) restores the brown fat phenotype in 
primary preadipocytes 
To determine whether brown fat development was restored in mice expressing 
Tyk2WTMyf5 and Tyk2KDMyf5, we isolated preadipocytes from 1-3 day old newborn pups 
and subjected them to in-vitro differentiation.  As seen in Figure 3.19A, expression of 
Tyk2WT and Tyk2KD restored the expression of brown fat specific genes (UCP1, cidea, 
PRDM16) and fat specific genes (PPARα, PGC1α). Also, muscle specific genes (MCK, 
MyoD) that were upregulated in Tyk2-/- mice were downregulated back to their normal 
levels in both Tyk2WT and Tyk2KD preadipocytes (figure 3.19B). This suggests that 
expression of Tyk2 in myf5 cre restores the brown fat phenotype in these mice. 
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Figure 3.19: Expression of Tyk2 in BAT rescues the brown fat phenotype: 
Expression of brown fat specific genes (UCP1, cidea, PRDM16) and fat specific genes 
(PPARa, PGC1a) (A) and muscle specific genes (MCK, MyoD) (B) in differentiated 
primary brow fat adipocytes measured by qRT-PCR. (n=3-5 mice per group). *p<0.05. 
**p<0.01. Data are expressed as mean ± SEM. 
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3.20: Restoring Tyk2 expression in BAT and SKM restores the thermogenic 
function of these tissues 
Since Tyk2-/- mice showed a defective response to cold exposure, we next determined 
whether Tyk2WTMyf5 and Tyk2KDMyf5 transgenics restored their ability for cold tolerance. 
12-14 week old mice were subjected to cold stress at 4oC for a period of 12 hours. Core 
body temperature was monitored at regular intervals. Figure 3.21 shows that both 
Tyk2WTMyf5 and Tyk2KDMyf5 can maintain the core body temperature as effectively as 
the Tyk2+/+ mice. This shows that function of SKM and BAT is not dependent on kinase 
activity of Tyk2. 
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Figure 3.20: Tyk2 expression in BAT and SKM restores the thermogenic function 
of these tissues: Core body temperature measured at 0.5, 1.5, 3, 6 and 12 hours using 
a rectal thermometer in 12-14 week old mice placed at 4oC for 12 hours. (n=3-7 mice 
per group) p<0.05. Data are expressed as mean ± SEM. 
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3.21: Restoring Tyk2 expression in the SKM alone reverts the obese phenotype in 
Tyk2-/- mice 
Since SKM is an important tissue controlling energy expenditure, we wanted to 
determine whether expressing Tyk2WT and Tyk2KD only in the SKM, but not BAT, of 
Tyk2-/- mice is sufficient to revert the obese phenotype. We crossed the Tyk2WT and 
Tyk2KD transgenic mice on Tyk2-/- background to mice carrying the cre recombinase 
under the MCK (muscle creatine kinase) promoter. This allows expression of the 
transgene in SKM and heart, but not BAT. The mice generated (along with Tyk2-/- and 
Tyk2+/+ controls) were weighed every week for a period of 6 months. As seen in Figure 
3.21A, at 12 weeks, Tyk2WTMCK and Tyk2KDMCK mice are significantly lighter than 
Tyk2-/- mice, but are still heavy compared to Tyk2+/+ mice. Interestingly, at 24 weeks 
(figure 3.21B), the Tyk2KDMCK mice show a complete reversal of obese phenotype, 
whereas Tyk2WTMCK mice show a moderate reversal. The effects seen are SKM 
specific, as the expression of genes involved in BAT function are downregulated, as in 
Tyk2-/- mice (Figure 3.21C). This suggests that expressing Tyk2 in the SKM alone can 
overcome the weight gain in Tyk2-/- mice and that kinase inactive form of Tyk2 is more 
effective in reversal of obese phenotype in Tyk2-/- mice. 
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Figure 3.21: Tyk2 expression in SKM alone partially reverts the obese phenotype 
in Tyk2-/- mice: Body weight of mice at A) 12 weeks B) 24 weeks fed a breeder chow 
diet. (n= 5-24 mice per group)  C) Expression of BAT specific genes-UCP1, PRDM16 
and cidea in BAT of 24 week old mice analysed by qPCR. ***p<0.0001, **p<0.01, 
*p<0.05. Data are expressed as mean ± SEM. 
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3.22: FERM domain of Tyk2 is required for the control of obesity  
From the previous figures, we can conclude that kinase activity of Tyk2, as a function of 
K927 in the JH1 domain, is dispensable for its role in regulating obesity, suggesting that 
Tyk2 may act as an adaptor protein and not as a kinase. Reports suggest that the N-
term FERM domain is important for protein-protein interaction of Tyk2. To determine 
whether the FERM domain is involved in mediating function of Tyk2 in obesity, we 
generated FERM domain deletion of Tyk2. Brown fat preadipocytes from Tyk2-/- mice 
were infected with these constructs and differentiated in- vitro. Oil-red O staining was 
used as a marker for differentiation. As seen in figure 3.22, deletion of FERM domain in 
both WT and KD forms of Tyk2, did not restore the differentiation of Tyk2-/- 
preadipocytes. This suggests that the FERM domain of Tyk2 may be involved in 
regulation of its function in obesity. 
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Figure 3.22: FERM domain of Tyk2 is important for its role in regulating obesity: 
Brown fat preadipocytes infected with the FERM domain deleted forms of Tyk2, sorted 
by FACS to selects cells expressing the tyk2 constructs (GFP) .Oil red-O staining was 
carried out after differentiation   N = 3. 
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3.23: Tyk2 interacts with transcription factors involved in BAT differentiation and 
function 
It has been well defined that the FERM domain of Tyk2 contains a nuclear-localization 
sequence (NLS) (54) and that Tyk2 also binds to the promoter region of IFN inducible 
genes along with its receptors IFNAR1 and IFNAR2 (55). We wanted to investigate 
whether the function of Tyk2 in obesity is because of its nuclear interactions. We 
immunoprecipitated Tyk2 from BAT of Tyk2WTMyf5 and Tyk2KDMyf5 mice and 
determined its interaction with transcription factors involved in BAT differentiation 
(PRDM16, C/EBPβ) and function (PGC1α,). As seen in Figure 3.25A, both Tyk2WT and 
Tyk2KD interact with PRDM16, C/EBPβ and PGC1α, suggesting that Tyk2 may be a 
part of the transcriptional complex regulating brown fat differentiation and function. We 
also performed a chromatin immunoprecipitation assay (ChIP) in brown fat of Tyk2+/+ 
mice with Tyk2 antibody and determined Tyk2 binding at the promoter regions of brown 
fat genes, UCP1 and PRDM16. As seen in Figure 3.23B, we did observe Tyk2 binding 
at these promoters and this binding is highly specific (figure 3.23C), suggesting a role 
for Tyk2 in regulating expression of genes involved in brown fat differentiation and 
function. 
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Figure 3.23: Tyk2 interacts with transcription factors involved in BAT 
differentiation and function: A) Whole cell extracts of BAT from Tyk2WTMyf5 and 
Tyk2KDMyf5 mice were immunoprecipitated with antibodies against Tyk2 and western 
blotted for PGC1α, C/EBPβ and PRDM16. IgG was used as unspecific control. N = 3. 
ChIP on BAT of 12 week old Tyk2+/+ mice. BAT from age matched Tyk2-/- mice were 
used as an unspecific control. qPCR was carried out to check for Tyk2 binding at  A) 
UCP1 and PRDM16 promotor regions B) different regions upstream of UCP1 promoter 
showing the specificity of Tyk2 binding. N = 3, ***p<0.001. 
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3.24: Interaction of Tyk2 with PGC1α is induced under starvation in SKM 
To further investigate whether the involvement of Tyk2 in skeletal muscle function is 
also beacuse of its nuclear interactions, we immunoprecipitated Tyk2 from SKM of 
Tyk2+/+ mice and determined its interaction with PGC1α which is important for skeletal 
muscle function. As seen in Figure 3.24, Tyk2 interacts with PGC1α, under starvation, 
when PGC1α levels are elevated (82). Interestingly, Tyk2 also interacts with the 
transcription factor C/EBPβ, which is involved in adult myogenesis. This suggests that 
Tyk2 may be a part of the transcriptional complex regulating skeletal muscle 
differentiation and function. 
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Figure 3.24: Tyk2 intercats with PGC1α in a starvation dependent fashion: Whole 
cell extracts of SKM Tyk2+/+ mice were immunoprecipitated with antibodies against 
Tyk2 and western blotted for PGC1α, C/EBPβ. IgG was used as unspecific control. 
N=3. 
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Chapter IV: Discussion 
The work presented in this thesis highlights the role of Tyk2 in regulating the 
development and function brown fat and skeletal muscle derived from the Myf5+ 
progenitors of the mesenchymal lineage. Our previous work characterized the functional 
defects in brown fat of Tyk2 deficient mice (70). 
Since we used a global knockout of Tyk2, the obese phenotype seen in the Tyk2 
deficient mice could be a function of not only brown fat, but also other important 
contributing factors including a defect in the regulation of energy balance mediated by 
the hypothalamus (83), decreased energy expenditure as a function of skeletal muscle  
(29, 44) and adipose tissue inflammation leading to insulin resistance (84). Skeletal 
muscle, like brown fat, is a mitochondria rich tissue, is important in regulating energy 
expenditure (38) and handles almost 80% of insulin mediated glucose uptake (30). 
Since both brown fat and skeletal muscle share common embryonic origins, we wanted 
to investigate the role of Tyk2 in skeletal muscle development and function. 
Interestingly, Tyk2 along with Jak2 has been observed in regulation of lineage specific 
determination of mouse embryonic stem cells (85). All JAKs are known to be expressed 
in mouse embryonic stem cells (mESCs). Tyk2 is phosphorylated along with JAK1 and 
JAK2 in mESCs following LIF treatment, suggesting their involvement in regulating 
mESC cell renewal (86).  
Body composition of Tyk2 deficient mice by NMR suggested that 3 month old knockout 
mice have an increased proportion of lean mass as compared to fat mass (A. Gornicka, 
unpublished data). Interestingly, brown adipose tissue also exhibited an increased 
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proportion of muscle specific genes (70), suggesting a dysregulation of the Myf5+ 
descendants.  The increased skeletal muscle mass could be a result of hypertrophied 
muscle. Cross sections of Tyk2 deficient skeletal muscle ruled out muscle hypertrophy, 
suggesting that there was an increase in overall number of skeletal muscle fibers in the 
Tyk2 deficient animals. Interestingly, as observed in brown fat, Tyk2 deficient mice did 
not exhibit an increased expression of skeletal muscle genes in the muscle. On the 
contrary, levels of muscle creatine kinase, which also regulates the phosphorylation of 
creatine, was downregulated in these mice. Phospho-creatine is a major source of fuel 
for the muscles. This suggested an energy imbalance (78) and insufficient supply of fuel 
to the muscles for contraction.  
Tyk2 deficient mice also show decreased expression of troponins, which are involved in 
regulating skeletal muscle contraction. This defect is observed even in newborn pups 
suggesting that the defects in muscle contraction are developmental and do not just 
accumulate with age. Previous studies by our group showed that Tyk2 deficient mice 
are exercise intolerant (69). This defect could be a function of impaired skeletal muscle 
contraction and/or dysfunctional mitochondria, which provide the necessary fuel for 
muscle contraction. Electron micrographs on skeletal muscle show smaller mitochondria 
with improper cristae formation in Tyk2 deficient mice. Interestingly, the number of 
mitochondria as observed in the different fiber types (both mitochondria rich type I and 
mitochondria poor Type II) was not much different between the wild type and Tyk2 
deficient mice. These mitochondria are not only structurally defective, but they also 
exhibit decreased oxygen consumption as a function of decreased activity of complex IV 
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of the ETC. This suggests a role for Tyk2 in regulating the skeletal muscle contraction 
and also mitochondria formation and function. 
Interestingly, expression of PGC1α, which is an important regulator of mitochondrial 
biogenesis, is also downregulated in Tyk2 deficient mice. PGC1α regulates the skeletal 
muscle fiber type determination (22). Tyk2 deficient mice exhibit an increased 
proportion of Type IIb (glycolytic) fibers, which have relatively low abundance of 
mitochondria. This could account for the exercise intolerant phenotype observed in Tyk2 
deficient mice.  
Numerous reports suggest the involvement of JAK-STAT pathway in regulating 
myogenesis (81, 87). JAK1 is required during initial myoblast proliferation stage 
whereas JAK2 is activated during the differentiation phage. JAK1 along with STAT1 and 
STAT3 also functions as a checkpoint to prevent myoblasts from premature 
differentiation. Knockdown of JAK1 induces increased myogenic differentiation with a 
concomitant reduction in cell proliferation  (88). Interestingly, JAK2 along with STAT2 
and STAT3 regulates the myoblast differentiation by activating the transcription factors 
MyoD and MFE2, which are involved in myogenic differentiation (81). As opposed to 
JAK1, knockdown of JAK2 inhibited myogenic differentiation, suggesting that JAK2 is 
required for skeletal muscle differentiation. JAK3, which was known to be restricted to 
the hematopoetic lineage, was also detected in proliferating myoblasts (89) and shown 
to play an inhibitory role on proliferating myoblasts. Apart from its involvement in 
myogenesis, JAK2 was found at the neuro-muscular junction along with ephrin receptor 
4A (Epr4A) and shown to regulate the expression of acetylcholine esterase, the critical 
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enzyme that hydrolyzed the neurotransmitter acetylcholine at the NMJ. This suggests a 
functional role for JAKs in regulating muscle contraction.  
We used an in-vitro system to determine whether Tyk2 plays a role in the development 
of skeletal muscle. During differentiation of C2C12 myocytes, we observed that Tyk2 
protein levels dramatically increase during the initial differentiation phase and stay 
elevated throughout differentiation. This increase is specific to Tyk2 and not other JAKs. 
This suggests that although Tyk2 levels are regulated during differentiation of skeletal 
muscle, it is dispensable for structural development of skeletal muscle. However, is  
required for the function of skeletal muscle.  
The development of obesity in Tyk2 knockout mice was a result of global Tyk2 
knockdown. Although expression of constitutively active Stat3 in the brown fat of Tyk2-/- 
mice, using the fat-specific ap2 cre (expresses in brown fat, white fat or both, after birth) 
reverted the obese phenotype (70), expression of Tyk2 transgene (Tyk2WT and 
Tyk2KD) in brown fat alone using the ap2 cre, was not sufficient to revert the obese 
phenotype (M. Derecka, unpublished data). This suggested that either Tyk2 has to be 
expressed in tissues other than brown fat and/or the timing of Tyk2 expression is very 
critical and needs to be expressed early in development. We addressed this issue of 
temporal and spatial regulation of Tyk2 using two cre systems. Using Myf5 cre, we 
expressed Tyk2 in both brown fat and skeletal muscle at E8.5 in the mouse embryo. We 
also used MCK cre, which allowed the expression of Tyk2 in skeletal muscle and heart, 
but not brown fat. Our earlier studies pointed that expressing a kinase inactive form of 
Tyk2 in Tyk2-/- brown fat preadipocytes can restore their differentiation in vitro 
(M.Derecka, unpublished data), suggesting that Tyk2 may not function as a kinase in 
108 
 
brown fat development. To this end, we generated two transgenic mouse lines that 
carried the wild type and kinase inactive allele of Tyk2. With both transgenes activated 
under the Myf5 promoter, we observed a complete reversal of the obese phenotype. 
This effect was observed as early as in 12 week old mice and the lean phenotype was 
maintained even in 6 month old animals. Cold exposure studies confirmed activation of 
thermogenesis in the transgenic mice, suggesting the functional rescue of both/either 
brown fat and skeletal muscle.  The in-vitro differentiation of brown fat preadipocytes 
was also recovered in both the transgenic lines, confirming the novel role of kinase 
inactive Tyk2 in brown fat differentiation and function.  
Using the MCK cre transgenic mice, we wanted to delineate whether expression of Tyk2 
in skeletal muscle was sufficient to revert the obese phenotype or it also required the 
function of brown fat.  12 week old Tyk2WTMCK and Tyk2KDMCK mice are significantly 
lighter than Tyk2-/- mice, but are still heavy compared to Tyk2+/+ mice. Interestingly, at 
24 weeks, the Tyk2KDMCK mice completely revert the obese phenotype, whereas the 
Tyk2WTMCK mice partially revert the obese phenotype. This suggests that the kinase 
activity of Tyk2 is not required for its role in skeletal muscle function. Interestingly, these 
results go along with our in-vitro brown preadipocyte differentiation model where we 
observe that kinase dead Tyk2 is more effective in rescuing the differentiation in Tyk2-/- 
preadipocytes. Why the kinase inactive Tyk2 appears to be more effective than the wild-
type form of Tyk2 is still not clear. One reason could be that the kinase activity of Tyk2 
may have an inhibitory role on its function. Since Tyk2 has been shown to have nuclear 
actions, it may be possible that Tyk2 could phosphorylate the histones and inhibit 
transcription of genes that regulate skeletal muscle function. Alternatively, the kinase 
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inactive Tyk2 is more effective in interacting with proteins regulating muscle function. 
More studies need to be carried out to address this issue. Unlike the reports suggesting 
that kinase inactive form of Tyk2 is prone to proteasomal degradation  (90), we did not 
see any differences in the expression of Tyk2 levels in our Tyk2KDMCK and Tyk2KDMyf5 
transgenic mice. Also, BAT development is not restored in these mice. This suggests 
that Tyk2 expression is required for proper skeletal muscle function and/or kinase 
activity of Tyk2 is inhibitory in skeletal muscle function. Co-expression of Tyk2 in brown 
fat and skeletal muscle may be required for optimal regulation of energy expenditure.  
Our results suggest that Tyk2 does not function as a classical JAK-STAT tyrosine 
kinase, since the kinase dead form of Tyk2 works as effectively as wild type Tyk2 to 
revert the obese phenotype in Tyk2 deficient mice. Non-classical functions of the JAK 
kinases are not unheard of. Until recently, involvement of JAKs in gene expression was 
thought to be restricted to their actions as receptor-associated tyrosine kinases, 
activating the STAT transcription factors. Recent reports suggest the presence of JAKs 
in the nucleus and also provide evidence that JAKs also can phosphorylate other target 
molecules apart from STATs (91). JAK2 in the nucleus was shown to phosphorylate 
Y41 on histone H3 and regulate genes involved in hematopoiesis and leukemia (52). 
Reports also suggest a nuclear localization of Tyk2 (54) and its role in gene regulation 
by binding to their promoters (55). On similar lines, we found an interaction of Tyk2 with 
PRDM16, PGC1α and C/EBPβ, the transcriptional complex regulating brown fat 
differentiation and function. In skeletal muscle, we found starvation-induced association 
of Tyk2 with PGC1α. The FERM domain deletion mutant of Tyk2, which is known to 
affect its nuclear localization, did not recover the differentiation capacity of Tyk2-/- 
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brown fat preadipocytes. This suggests that nuclear actions of Tyk2 are required for its 
role in regulation and differentiation of the thermogenic tissues. We speculate that Tyk2, 
along with PRDM16, may be a part of the transcriptional machinery regulating the 
brown fat differentiation.  
Our studies suggest that Tyk2 is required at two different stages of development. First, it 
may be required for the commitment of the Myf5+ progenitors towards developing 
brown fat and plays an inhibitory role towards commitment of these progenitors towards 
skeletal muscle (Figure 4.1). Secondly, Tyk2 may also be required for the function of 
brown fat and skeletal muscle, by regulating the expression of genes involved in brown 
fat and skeletal muscle differentiation and/or function (Figure 4.2). It is also interesting 
to note that levels of Tyk2 in the skeletal muscle are much lower compared to other 
tissues in a mouse (70), suggesting that Tyk2 may play an inhibitory role in 
maintenance of skeletal muscle progenitors. The role of Tyk2 needs to be further 
explored with respect to what other genes does it control, how is it activated in response 
to cold and what other proteins it interacts with.  
Therapies for obesity include increasing energy expenditure by exercise and reducing 
caloric intake. Unfortunately, only a small proportion of obese individuals are able to 
maintain their reduced body weight on a diet and exercise regime. Bariatric surgery is 
recommended for extreme obese patients, however it also comes with side effects  (5). 
As of today, FDA has approved three drugs for treatment of obesity which aim at 
decreasing energy intake. Sibutramine and Phentermine act on the satiety centers in 
the brain and thus control food intake by obese individuals. Orlistat reduces absorption 
of fatty acids in the intestine (92). However, apart from the unpleasant side effects that 
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these drugs possess, clinical studies on patients have shown that once the treatment is 
stopped, weight gain is accelerated, thus limiting the success of these treatments. 
Reducing caloric intake also triggers the starvation response in mammals, which may 
also reduce the efficacy of these drugs.  
The other promising treatment for obesity is increasing energy expenditure. Increasing 
the thermogenic potential of brown fat and skeletal muscle could provide means to 
increase energy wasting by these tissues, thus potentiating their anti-obesity effects. 
However, increasing energy expenditure has to be maintained in a controlled manner. If 
the inherent function of brown fat and skeletal muscle could be modified, which would 
change the basal metabolic rate (BMR) of an individual, these effects would be 
beneficial in the long run. In the 1930s, mitochondrial uncoupler 2, 4 dinitrophenol 
(DNP) gained popularity as an anti-obesity drug. DNP, like UCP1, created a proton leak 
in the mitochondrial membrane, thus dissipating the potential energy as heat.  Although 
DNP was successful in reducing obesity, continuous use of DNP generated unwanted 
side effects including hyperthermia, which resulted in death in some cases. Hence, 
when aiming to develop drugs that increase energy expenditure, careful considerations 
about not expending excessive energy should be taken into account. If a balance 
between energy intake and expenditure could be maintained, that will be a better way to 
combat obesity.  
Given the role of Tyk2 in regulating function of brown fat and skeletal muscle, controlled 
activation of Tyk2 to improve the energy expenditure in these thermogenic tissues could 
provide an attractive therapy for treatment of obesity.  
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Figure 4.1: Tyk2 may be required for the commitment of Myf5+ progenitors: Tyk2 
may be required along with PRDM16 for commitment of Myf5+ mesenchymal stem cells 
towards brown adipocytes and may also play an inhibitory role in commitment of the 
Myf5+ cells towards skeletal muscle development.  
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Figure 4.2: Tyk2 regulates genes involved in BAT and SKM differentiation and/or 
function: Tyk2 may be a part of a multiprotein transcriptional complex regulating genes 
involved in BAT and SKM differentiation/function.  
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